## SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia

Kai Qin,<sup>1,9</sup> Kazuhito Honjo,<sup>1,9</sup> Scott Sherrill-Mix,<sup>2,9</sup> Weimin Liu,<sup>2,9</sup> Regina Stoltz,<sup>2,9</sup> Allisa K. Oman,<sup>1</sup> Lucinda A. Hall,<sup>3</sup> Ran Li,<sup>1</sup> Sarah Sterrett,<sup>1</sup> Ellen R. Frederick,<sup>1</sup> Jeffrey R. Lancaster,<sup>1</sup> Mayur Narkhede,<sup>1,4</sup> Amitkumar Mehta,<sup>1,4</sup> Foluso J. Ogunsile,<sup>1</sup> Rima B. Patel,<sup>1</sup> Thomas J. Ketas,<sup>5</sup> Victor M Cruz Portillo<sup>5</sup>, Albert Cupo<sup>5</sup>, Benjamin M. Larimer,<sup>3,4</sup> Anju Bansal,<sup>1,4</sup> Paul A. Goepfert,<sup>1,4,6</sup> Beatrice H. Hahn,<sup>2,7</sup> and Randall S. Davis<sup>1,4,6,8,10\*</sup>

<sup>1</sup>Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA

<sup>2</sup>Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>3</sup>Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA

<sup>4</sup>O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA

<sup>5</sup>Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA

<sup>6</sup>Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA

<sup>7</sup>Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>8</sup>Department of Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA

<sup>9</sup>These authors contributed equally

<sup>10</sup>Lead Contact

\*Correspondence: rsdavis@uab.edu (R.S.D.)

#### **SUMMARY**

Chronic lymphocytic leukemia (CLL) patients have lower seroconversion rates and antibody titers following SARS-CoV-2 vaccination, but the reasons for this diminished response are poorly understood. Here, we studied humoral and cellular responses in 95 CLL patients and 30 healthy controls after two BNT162b2 or mRNA-2173 mRNA immunizations. We found that 42% of CLL vaccinees developed SARS-CoV-2-specific binding and neutralizing antibodies (NAbs), while 32% had no response. Interestingly, 26% were seropositive, but had no detectable NAbs, suggesting the maintenance of pre-existing endemic human coronavirus-specific antibodies that cross-react with the S2 domain of the SARS-CoV-2 spike. These individuals had more advanced disease. In treatment-naïve CLL patients, mRNA-2173 induced 12-fold higher NAb titers and 1.7-fold higher response rates than BNT162b2. These data reveal a graded loss of immune function, with pre-existing memory being preserved longer than the capacity to respond to new antigens, and identify mRNA-2173 as a superior vaccine for CLL patients.

#### **INTRODUCTION**

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in Western countries and mainly affects the elderly, with a median age at diagnosis of 70 years. Because the natural progression of this B cell malignancy as well as its treatments weaken adaptive and innate immunity, infections are a leading cause of death. Most patients are followed with a 'watch and wait' strategy for years until they meet criteria for therapy. However, vaccine responses even in treatment-naïve patients are impaired and many require intravenous immunoglobulin (IVIg) infusions to mitigate infections. The mechanisms responsible for the loss of immune function are still poorly understood.

Since their emergence hundreds of years ago, <sup>10</sup> four human coronaviruses (HCoV-229E, HCoV-NL63, HCoV-HKU1, and HCoV-OC43), which cause mild seasonal upper respiratory infections, <sup>11</sup> have become endemic. However, more recently there have been zoonotic outbreaks of three pathogenic HCoVs, including severe acute respiratory syndrome-coronavirus (SARS)-CoV, Middle East Respiratory Syndrome (MERS)-CoV, and most recently SARS-CoV-2. The coronavirus disease of 2019 (COVID-19) pandemic caused by SARS-CoV-2 has resulted in the deaths of over 6 million people globally and over 1 million in the United States. <sup>12</sup> Severe illness and mortality are especially high in older individuals with comorbidities and compromised immunity. <sup>13, 14</sup> Hence, the SARS-CoV-2 pandemic has posed a particularly difficult challenge for CLL patients, which is underscored by two international studies that demonstrated COVID-19 fatality rates of ~27-38%. <sup>15, 16</sup> Although mortality rates have decreased with mitigation strategies and the evolution of less pathogenic variants, <sup>17</sup> preventing SARS-CoV-2 infection in these individuals remains a high priority.

SARS-CoV-2 enters human respiratory epithelial cells following the binding of the viral spike (S) glycoprotein receptor binding domain (RBD), located within the S1 subunit, with the host angiotensin-converting enzyme 2 (ACE2) receptor.<sup>18, 19</sup> Thus, neutralizing antibodies

(NAbs) that disrupt RBD/ACE2 binding and viral entry represent a key defense. NAbs represent an important correlate of immune protection, as evidenced by the beneficial effects of convalescent plasma (CP) and recombinant NAbs in patients who are unable to mount an adequate antiviral response.<sup>20-22</sup> In addition, NAbs prevent symptomatic SARS-CoV-2 infection in immunocompetent hosts.<sup>23</sup>

Multiple reports indicate diminished immune responses in CLL patients following COVID-19 mRNA vaccination, <sup>24-26</sup> but the reasons for this decreased reactivity even in treatment-naïve patients remain largely unknown. Here we studied humoral and cellular immune responses in a clinically well-characterized cohort of SARS-CoV-2 infection-naïve CLL patients and healthy controls following two immunizations with the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-2173) mRNA vaccines. Consistent with previous reports, we show that both cellular and humoral vaccine-induced responses are reduced in CLL patients. Moreover, vaccinees exhibited a wide variety of antibody responses, ranging from only moderately diminished binding and NAb titers to a complete absence of detectable antibodies. One group of vaccinees was of particular interest since they failed to develop SARS-CoV-2 specific NAbs, but had high-titer binding antibodies that preferentially reacted with the S2 subunit of the SARS-CoV-2 spike. Since these individuals also exhibited high-titer seroreactivity to endemic HCoVs, their anti-HCoV antibodies likely cross-reacted with conserved regions of the SARS-CoV-2 spike. Thus, SARS-CoV-2 vaccination exposed a graded decline in immune function, with a subset of CLL patients still being able to maintain, and possibly boost, pre-existing immune responses, while having lost the ability to respond to new antigens.

## **RESULTS**

## **Study participants**

We recruited 95 patients diagnosed with CLL according to IWCLL criteria³ and 30 healthy controls with no prior SARS-CoV-2 infection as determined by a lack of nucleocapsid antibodies. All participants received two doses of either the Pfizer BNT162b2 or the Moderna mRNA-2173 vaccine, both of which encode the SARS-CoV-2 Wuhan 1 spike protein. Clinical characteristics of the enrolled CLL patients and healthy controls are provided in Tables 1 and S1. The median age of the CLL patients was 72 years (IQR, 64-77) and 47 were male. Forty-five of the patients (47%) were treatment-naïve, whereas 50 (53%) had prior therapy, including 34 who were actively treated (i.e., anti-CD20 therapy, Bruton's tyrosine kinase [BTK] inhibition). Seven individuals were refractory to therapy and relapsed, and nine were off-therapy in clinical remission. Sixty-one patients (64%) received 30 μg of the Pfizer BNT162b2 vaccine, while 34 (36%) were immunized with 100 μg of the Moderna mRNA-2173 vaccine according to FDA guidelines. The median time period from the second immunization to testing was 38 days (IQR, 26-83) for CLL donors and 35 days (IQR, 28-56.5) for healthy controls.

## Binding and neutralizing antibody responses in CLL patients correlate with disease status

Plasma samples from all CLL vaccinees and healthy controls were tested for SARS-CoV-2 antispike and RBD binding antibodies by ELISA as described. While all control subjects generated both anti-S and RBD IgG following immunization, response rates were significantly reduced in CLL patients, with only 65 (68%) developing anti-S and 51 (54%) developing RBD antibodies (Tables S2 and S3). CLL vaccinees also had 23-fold lower anti-S and 30-fold lower RBD half-maximal effective concentrations (EC<sub>50</sub>) compared to healthy controls (Figures 1A and 1B). Even when comparing only CLL patients who mounted a humoral response (i.e., CLL responders), we found median IgG anti-S and RBD EC<sub>50</sub> values that were 7.2-fold and 6.4-fold lower than those of healthy controls, respectively (Tables S2 and S3).

We next explored whether there was an association between seroreactivity and disease history. As expected, treatment-naïve patients had higher response rates and anti-S Ab titers (median 2,733) compared to vaccinees on active CLL therapy (median <100) (Figure 1C). All CLL patients who were in clinical remission (CR) mounted anti-S responses and had significantly higher IgG titers (median 2,740) compared to those on treatment. RBD response rates and Ab titers were also higher for individuals who were treatment-naive or in clinical remission compared to actively treated patients, and vaccinees who were refractory to therapy or relapsed (R/R) had generally lower anti-S and RBD responses (Figures 1C and 1D).

Although most individuals who were treatment-naive or in clinical remission had anti-S and RBD IgG binding antibodies, their titers were significantly lower compared to controls (Figures 1A-1D).

We next analyzed plasma samples for neutralizing activity against the SARS-CoV-2 D614G<sup>28</sup> and B.1.617.2 (also known as delta)<sup>29, 30</sup> variants using an HIV-1-based pseudovirus assay.<sup>31</sup> Consistent with the ELISA findings, neutralizing responses in CLL patients were overall reduced. While NAbs against the D614G and delta variants were found in 97% and 93% of healthy controls, respectively, NAb response rates in CLL patients were significantly lower at 42% (40/95) and 38% (35/93) (Tables S2 and S3). An assay that measured Ab-mediated inhibition of the ACE2/RBD (Wuhan strain) interaction,<sup>22</sup> yielded very similar results, detecting blockade in all controls, but in only 30% (28/95) of CLL patients (Tables S2 and S3). Median NAb titers were also significantly lower in CLL patients than healthy controls, with half-maximal inhibitory dilutions (ID<sub>50</sub>) for D614G being >23-fold (464 vs  $\leq$  20; Figure 1E) and Delta being >17-fold (346 vs  $\leq$  20; Figure 1F) lower, respectively. Similarly, ACE2/RBD inhibition was lower in CLL patients (Figure 1G). Finally, neutralizing responses in CLL patients reflected their disease and treatment status. Response rates, NAb titers, and ACE2/RBD blockade were all significantly higher in individuals who were treatment-naive or in clinical remission compared to individuals on active treatment or in relapse (Figures 1H-1J). These data confirm and extend

earlier findings,<sup>24, 25, 32</sup> showing impaired humoral responses not only in treated but also in treatment-naïve CLL patients.

## Clinical predictors of humoral immune responses in vaccinated CLL patients

To search for predictors of humoral responses following immunization, we analyzed the demographics and disease characteristics of CLL vaccinees. By univariate analysis we compared 18 clinical variables with binding (anti-S and RBD IgG) and neutralizing (D614G, Delta, and ACE2/RBD blockade) antibody responses, measured as binary parameters (Tables 1, S1, and S4). Examining the four CLL groups (treatment-naive, active therapy, clinical remission, and refractory/relapsed), disease status itself was significantly associated with responsivity (Table S4A). Clinical determinants that correlated with higher IgG titers and neutralizing activity included early Rai stage disease, low serum β2-microglobulin (≤2.4 mg/L) levels, lack of prior CLL therapy, vaccination ≥ 12 months following anti-CD20 therapy, and no requirement for IVIg therapy. Since D614G and Delta NAb titers were largely equivalent, to determine clinical risk factors associated with a failure to mount anti-S IgG and/or NAb responses, we performed a multivariate analysis using only the D614G NAb data (Table S4B). As expected, active therapy was a significant adverse predictor of both anti-S binding (OR, 62; 95% CI, 3.6-3500) and D614G NAbs (OR, 40; 95% CI, 1.2-2500), whereas being refractory to therapy (OR, 7.7; 95% CI, 1.1-64) and requiring prophylactic IVIg therapy (OR, 5.2; 95% CI, 1.3-29) were both associated with poor humoral responses. Unexpectedly, BNT162b2 vaccination was also a negative predictor of D614G NAbs (OR, 5.8; 95% CI, 1.6-27), suggesting vaccinespecific differences in neutralizing antibody elicitation.

## Vaccinated CLL patients have reduced CD4<sup>+</sup> but relatively preserved CD8<sup>+</sup> T cell functions

To investigate the impact of vaccination on cell-mediated immunity, we examined peripheral blood mononuclear cells (PBMCs) from a subset of vaccinated CLL patients (n=36) and healthy controls (n=21) for which sufficient samples were available (Table S5). The frequencies of circulating total CD3+, CD4+, and CD8+ T cells as well as naïve and memory subsets were determined by multi-color flow cytometry analysis with CD45RA and CCR7 immunophenotyping (Figure S1 and Table S5A). As expected, total CD3+ T cell frequencies were significantly higher in controls than CLL vaccinees (Figure S1A). Immunophenotypic analysis showed skewing of the CLL T cell compartment, with lower total CD4+ and higher CD8+ T cell numbers, resulting in lower CD4:CD8 ratios compared to controls (Figures S1B-S1D). Among T cell subsets, CLL vaccinees had relatively lower frequencies of naïve CD4+ and CD8+ T cells (Figures S1E and S1F). In contrast, CLL effector memory CD8+, but not CD4+, T cell frequencies were higher. However, central memory and terminally differentiated effector memory RA T cells did not differ between the groups. These results confirmed previous findings, 33-36 indicating lower naïve CD4+ and CD8+ T cell populations as well as higher effector memory CD8+ T cells in CLL vaccinees compared to healthy controls.

To examine antigen-specific function, we determined activation-induced marker (AIM) expression for CD4<sup>+</sup>, circulating T follicular helper cell (cTfh), and CD8<sup>+</sup> T cells following S and N peptide pool (Wuhan strain) stimulation. For both CD4<sup>+</sup> T and cTfh cells, antigen specificity was quantified by the frequency of PD-L1 and OX40 co-expressing cells, while the CD69<sup>+</sup>CD137<sup>+</sup> population was used to identify CD8<sup>+</sup> T cells (Figure S2A; Tables S5B and S5C). Although all subjects lacked nucleocapsid (N) antigen seroreactivity, AIM T cell responses against N peptides were detected in the CD8<sup>+</sup> T cells of one healthy control and the CD4<sup>+</sup> T cells of three CLL patients, likely representing responses to prior endemic HCoV infections

(Table S5B).<sup>37, 38</sup> In contrast, overall responses against S peptides were found in 91% of controls, but only 33% of CLL patients (Table S5C). S-restricted responder rates for CLL vaccinees were also significantly lower for each of the three T cell subsets analyzed (Figure 2A). Moreover, the median frequencies of S reactive AIM responding cells among the three T cell subsets were significantly reduced in CLL vaccinees compared to healthy controls (Figure 2B). These findings demonstrate lower antigen-specific responses by different T cell subsets in CLL patients following SARS-CoV-2 mRNA vaccination.

We next tested CD4<sup>+</sup> and CD8<sup>+</sup> T cell function by quantifying cytokine and effector molecule production by intra-cellular staining (ICS). To exclude potential effects of prior HCoV infections, only healthy controls (n=15) and CLL (n=7) samples with positive S and negative N peptide responses were analyzed. ICS positivity was defined by a T cell response to at least one of five parameters: IFN $\gamma$ , IL-2, TNF $\alpha$ , CD107a plus granzyme B, or CD107a plus perforin (Figure S2B). S-restricted CD4<sup>+</sup> T cell responses were significantly higher in controls compared to CLL vaccinees (Figure 2C and Table S5D), with most pronounced differences observed for IFN<sub>V</sub> (Figure 2D). By combinatorial polyfunctionality analysis.<sup>39</sup> a higher score for CD4<sup>+</sup> T cells indicated more robust effector function for this subset in healthy controls compared to CLL vaccinees (Figure 2E). In contrast, the responder rate and single or polyfunctionality quantitation for CD8<sup>+</sup> T cells was comparable between the cohorts, although CLL vaccinees showed a trend toward lower IFNγ production. The difference between CD4+ and CD8+ T cell function was generally consistent between the AIM and ICS analyses. Univariate analyses to define potential clinical correlates with these T cell studies failed to identify significant associations, likely reflecting the low response frequencies and testing of a subset of the total cohort. Overall, these data indicate reduced S-restricted CD4<sup>+</sup> T cell effector functions, but relatively preserved CD8<sup>+</sup> T cell functions in CLL vaccinees.

#### Vaccinees who lack SARS-CoV-2 NAbs maintain antibodies to endemic coronaviruses

An analysis of the serologic data in Figure 1 showed that 32% of all CLL patients failed to seroconvert or develop D614G NAbs following vaccination (S<sup>-</sup>NAb<sup>-</sup>), while 42% developed both anti-S binding antibodies and NAbs (S<sup>+</sup>NAb<sup>+</sup>) (Figure 3A). Unexpectedly, 26% of CLL vaccinees had anti-S binding antibodies, but lacked detectable NAbs (S<sup>+</sup>NAb<sup>-</sup>). This was not due to IVIg treatment, since among the 25 IVIg treated CLL patients 14 were S<sup>-</sup>NAb<sup>-</sup> and 6 were S<sup>+</sup>NAb<sup>-</sup>. Instead, the data suggested that some CLL patients had selectively lost their ability to generate NAbs despite exhibiting anti-S reactivity. To examine this unusual phenotype, we compared S and RBD binding antibody titers in S<sup>+</sup>NAb<sup>+</sup> and S<sup>+</sup>NAb<sup>-</sup> CLL patients. Median IgG titers against these two antigens were 3 to 4-fold lower for S<sup>+</sup>NAb<sup>+</sup> CLL patients compared to healthy controls, but were even more diminished for individuals with S<sup>+</sup>NAb<sup>-</sup> status, i.e., 23-fold and 35-fold, respectively (Figures 3B and 3C).

One potential explanation for the S\*NAb\* serologic phenotype was the presence of cross-reactive antibodies from prior HCoV infections. To investigate this possibility, we tested all S\*NAb\* CLL patients (n=25) and a subset of the healthy controls (n=15) for IgG binding to recombinant spike proteins of six HCoVs: SARS-CoV, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63, and HCoV-229E. We found that IgG EC<sub>50</sub> titers against the SARS-CoV spike, which shares ~75% ectodomain sequence identity with SARS-CoV-2, <sup>18, 19</sup> were significantly lower for S\*NAb\* CLL patients than controls, and a similar trend was observed for the more distantly related MERS-CoV spike. However, no such differences were found for the other HCoV spike proteins, against which high-titer antibodies were detected in both CLL vaccinees and heathy controls (Figure 3D). Thus, while S\*NAb\* vaccinees were unable to produce SARS-CoV-2 specific NAbs, they maintained high-titer HCoV-specific antibodies that cross-reacted with the spike proteins of SARS-CoV and MERS-CoV.

To further dissect the S\*NAb⁻ serotype, we analyzed available samples from S\*NAb⁻ CLL vaccinees (n=19) and healthy controls (n=15) for IgG binding against the SARS-CoV-2 S1 and S2 subunits by ELISA. CLL EC₅₀ titers against these two S proteins were again significantly lower compared to controls; however, this difference was much more pronounced for S1 (52-fold) than S2 (1.7-fold) (Figures 3E and 3F, Table S2). Moreover, a paired donor analysis of S1 and S2-IgG EC₅₀ titers revealed that S⁺NAb⁻ CLL vaccinees had higher S2 titers than the controls who had elevated S1 titers (Figure 3G). This S2 bias remained significant even when median differences in S2-S1 titers were subtracted. Taken together, these data suggest that S⁺NAb⁻ vaccinees were able to maintain, and possibly even boost, pre-existing HCoV antibodies that cross-reacted with conserved epitopes in the S2 subunit of SARS-CoV-2. Unfortunately, the latter possibility could not be tested since pre-vaccination samples were not available.

The mRNA-1273 vaccine elicits superior NAb responses in treatment-naive CLL patients

A multivariate analysis identified significantly higher D614G NAb response rates in CLL patients
vaccinated with mRNA-2173 (53%, 18/34) compared to those vaccinated with BNT162b2 (36%,
22/61), despite very similar treatment and clinical states (Fisher's exact test, p = 0.73) (Figure
4A, Table S4B). To examine the reason for this difference, we compared NAb ID<sub>50</sub> titers in all
patients by vaccine type. Remarkably, both the median D614G and Delta ID<sub>50</sub> NAb titers of
mRNA-2173 immunized CLL patients were significantly higher than those of CLL vaccinees who
received BNT162b2 (Figures 4B and S3A). Because a large number of patients was unable to
mount a humoral response because of CLL-directed immunosuppressive therapy (Figure 4B,
red samples), we next focused on treatment-naïve BNT162b2 (n=30) and mRNA-2173 (n=15)
CLL vaccinees. Again, these two groups did not differ in parameters of clinical progression,
including Rai stages, absolute lymphocyte counts (ALC), serum β2M levels, and IVIg
prophylaxis requirements (Figure 4C). Although only 28 of 45 treatment-naïve CLL vaccinees

developed D614G NAbs, the response rates were significantly higher for mRNA-2173 (13/15, 87%) than for BNT162b2 (15/30, 50%) recipients (Figure 4D). Accordingly, mRNA-2173 vaccinees had 6.5-fold higher odds (95% CI, 1.3-31.7) of NAb development than BNT162b2 recipients. Similar results were obtained for the Delta variant, where 11 of 15 (73%) mRNA-2173 vaccinees mounted detectable NAbs compared to 13 of 30 (43%) BNT162b2 recipients, although these differences did not reach significance (Figure S3B). Finally, both D614G and Delta NAb titers were significantly higher in mRNA-2173 compared to BNT162b2 recipients (Figures 4E and S3C), despite very similar clinical characteristics (Figure 4C). Thus, the inferior NAb responses in CLL patients immunized with BNT162b2 were a consequence of the vaccine type and not differences in disease progression.

That fact that there were comparable numbers of D614G NAb+ (n=15) and NAb- (n=15) individuals who received the BNT162b2 vaccine provided an opportunity to examine reasons for these differences. The average time from the second vaccination to sample collection did not differ between the NAb+ and NAb- groups (64.7 vs 67.3 days). However, comparisons of clinical parameters indicated a trend toward more advanced disease in NAb+ CLL vaccinees, with higher Rai stage, increased serum β2M levels, and IVIg requirements that were absent in NAb+ CLL vaccinees (Figure 4F). These disease characteristics also correlated with poor D614G NAb responses when the entire CLL cohort was analyzed (Table S4A). Among treatment-naïve BNT162b2 vaccinees, elevated serum β2M was associated with a 3.5-fold higher risk of failing to mount a D614G NAb response (95% CI, 1.8-7.2, p = 0.003). Due to limited sample numbers, Rai stages II-IV and IVIg therapy alone were not predictive, but when considered in combination, their presence predicted a 2.7-fold higher risk of failing to develop NAbs (95% CI, 1.4-4.7, p = 0.02). Similar results were obtained when NAb titers to the Delta variant were compared, with elevated serum β2M conferring a 2.6-fold higher risk (95% CI, 1.4-4.8, p = 0.02) and the combination of Rai stages II-IV and IVIg therapy conferring a 2.4-fold higher risk (95%

CI, 1.5-4.3, p=0.004) of impaired NAb responses (Figure S3D). These findings indicate that CLL vaccinees who are unable to develop NAb responses possess features of advanced clinical disease.

Treatment-naïve CLL vaccinees who are unable to mount NAb responses have lower CD4<sup>+</sup> T cells

Interactions between CD4+ T and B cells are critical for germinal center reactions. 40,41 Because these lymphocyte subsets decline as a function of both age and CLL disease, 2,42,43 we compared T cell frequencies in age-matched healthy controls (n=7) as well as treatment-naïve SARS-CoV-2 vaccinees who did (S+NAb+, n=11) versus did not (S+NAb+, n=9) mount a neutralizing antibody response. As observed for the overall CLL cohort (Figure S1), total CD3+ T cells were significantly reduced in S+NAb+ and S+NAb+ patients relative to controls (Figure 5A). However, S+NAb+ vaccinees had significantly lower numbers of total CD4+ T cells and a trend toward higher CD8+ frequencies, as reflected by lower CD4:CD8 ratios (Figures 5B-5D). Similar trends were evident for naïve and memory CD4+ and CD8+ subsets. Compared to controls, naïve CD4+ T cells were significantly lower in S+NAb+, but not S+NAb+ patients, while there was a coincident rise in effector memory CD8+ T cells in the former group (Figures 5E and 5F). These data indicate an association between lower naïve CD4+ T cell numbers and the inability of treatment-naive CLL patients to generate NAb responses.

#### **DISCUSSION**

CLL is a slowly advancing B cell lymphoproliferative disorder that ultimately impairs the ability to mount an effective immune response to new infections. Here, we compared the immunogenicity of BNT162b2 and mRNA-2173 SARS-CoV-2 vaccines in a clinically well-characterized cohort of

CLL patients and discovered a previously unappreciated progressive loss of adaptive immune functions in treatment-naive CLL patients (Figure 6). By examining both binding and neutralizing antibody responses, we found a subset of vaccinees that was still able to mount de novo responses to SARS-CoV-2 antigens, albeit at titers lower than healthy controls (S+NAb+, light green). A second group of CLL vaccinees was unable to generate SARS-CoV-2 neutralizing antibodies (S<sup>+</sup>NAb<sup>-</sup>, yellow), but had spike binding antibodies which primarily reacted with epitopes in the SARS-CoV-2 S2 subunit. Although these could be vaccine-induced SARS-CoV-2 directed antibodies, it is more likely that they represent recall responses of pre-existing anti-HCoV antibodies that cross-react with conserved S2 epitopes. The latter possibility is reminiscent of the concept of antigenic imprinting or original antigenic sin.<sup>44</sup> which refers to the preferential reactivation of cross-reactive memory B cells from an initial antigenic exposure, rather than the initiation of *de novo* responses when encountering a new related antigen. The fact that S<sup>+</sup>NAb vaccinees had more advanced disease with lower naïve CD4<sup>+</sup> and higher CD8<sup>+</sup> effector memory T cells is consistent with this interpretation. The third group of CLL vaccinees had no detectable SARS-CoV-2 antibodies (S NAb, light red), indicating an inability to mount de novo as well as recall responses. Most of these individuals required IVIg prophylaxis, demonstrating they were the most immune compromised. Thus, SARS-CoV-2 vaccination exposed a progressive loss of immune functions in CLL patients, with pre-existing memory being preserved longer than the capacity to respond to new antigens (Figure 6).

Although we cannot exclude that S<sup>+</sup>NAb<sup>-</sup> CLL patients mounted some *de novo* responses, the absence of detectable neutralizing antibodies indicates that these individuals lacked key immune elements required for the induction of germinal center B cell responses and antibody affinity maturation. This disparate humoral response was accompanied by diminished frequencies and altered functions of T cells that were more biased towards a CD8<sup>+</sup> response. Nonetheless, S<sup>+</sup>NAb<sup>-</sup> CLL vaccinees maintained HCoV-specific antibodies at levels comparable

to healthy controls. Thus, SARS-CoV-2 vaccination in the context of a partially compromised immune system may favor reactivation of pre-existing memory over the stimulation of naïve B cells, similar to what has been observed for responses to influenza following vaccination in the elderly. Given the essential contributions of naïve B and CD4+ T cells to *de novo* responses, their decline over the CLL disease course is expected to worsen the capacity for engaging neoantigens. Germinal center-based functions would be increasingly diminished and the potential for generating new responses would eventually be lost. Our study thus suggests that vaccination against SARS-CoV-2 or other neoantigens could be used as a tool to assess the status of this decline and to gain greater insight into the underlying mechanisms contributing to the immune impairment.

Recent studies have shown that CLL patients benefit from adjuvanted zoster vaccines, including individuals on BTK inhibition, but that hepatitis B immunization elicited poor or no responses in both treatment-naive and BTK inhibitor treated patients. The effectiveness of pneumococcal and influenza immunization is also low in treatment-naive CLL patients, but has been observed to improve with higher dosing, adjuvant-conjugation, and earlier administration following diagnosis. These results suggest that CLL patients with a reduced ability to mount *de novo* responses may benefit from more rationally designed vaccine regimens. Indeed, about a quarter of CLL patients who failed to respond to two SARS-CoV-2 mRNA immunizations, subsequently seroconverted following a third immunization. Thus, CLL patients should be considered candidates for alternative vaccination strategies. For example, the high-dose flu vaccine, which is tailored for the elderly, may elicit stronger and broader responses in CLL patients with partially impaired adaptive immunity. Similarly, a COVID vaccine that includes more than one variant may improve *de novo* responses. Clinical trials that formally test these possibilities should be of high priority.

For treatment-naive patients who lack humoral responses (S<sup>-</sup>NAb<sup>-</sup>) or those on B cell targeted therapies that inhibit seroconversion or NAb generation, passive immunotherapies and antivirals will continue to be important. More than 25% of CLL patients require IVIg<sup>9</sup> and recent studies confirm the presence of NAbs in US preparations.<sup>48</sup> Prophylactic administration of recombinant NAbs have also proved beneficial in the immunocompromised.<sup>49</sup> However, it is difficult for these treatments to keep up with the pace of viral diversification and resistance to antivirals will likely also occur.<sup>50</sup> Given the benefits of polyclonal convalescent plasma,<sup>22</sup> a cocktail of prophylactic recombinant NAbs engineered for breadth and durability will thus be a critical advance for this patient population.

A key finding in our study was the demonstration of superior neutralizing antibody responses in CLL patients who received the mRNA-2173 vaccine. This observation is consistent with previous findings of improved seroconversion rates and T cell activity in COVID vaccine studies of other hematologic malignancies, including CLL,<sup>25, 47, 51</sup> as well as immunocompromised patients with non-malignant conditions such as solid organ transplant or rheumatologic disorders.<sup>52</sup> The higher neutralizing response rates and titers in mRNA-2173 vaccinees may be due to the mRNA dose, which is ~3.3-fold higher compared to BNT162b2.<sup>53, 54</sup> Indeed, in the elderly, a 100 μg mRNA-1273 dose elicited higher binding and neutralizing antibody titers than a 25 μg dose.<sup>55</sup> However, the two vaccines also differ in other properties, including their formulation.<sup>56</sup> Regardless of the reasons, the fact that the mRNA-2173 vaccine elicited higher NAb titers in a larger fraction of CLL patients suggests that this vaccine may confer greater protection from SARS-CoV-2 in this vulnerable population.

In summary, our study of SARS-CoV-2 vaccine-induced humoral and cellular responses in CLL patients provides a more nuanced picture of their inherent immune dysfunction, with pre-existing immunity being preserved longer than the capacity to mount *de novo* responses.

Moreover, higher NAb titers and response rates identify mRNA-2173 as a potentially superior

vaccine in CLL patients. Future studies should consider the utility of vaccination to assess the extent of disease-induced immune dysfunction in CLL patients and to gain greater insight into the underlying mechanisms.

#### **ACKNOWLEDGEMENTS**

We thank the donors and patients who contributed samples as well as the UAB Hematology/Oncology staff who supported this study. These studies were funded in part by the UAB School of Medicine Dean's office COVID-19 research initiative, the UAB Cancer Immunobiology Program, and grants from the NIH (UM1 Al069452, R01 Al150590, and U01 CA260462).

#### **AUTHOR CONTRIBUTIONS**

Conceptualization, A.B., P.A.G., B.H.H., and R.S.D.;

Methodology, K.Q., K.H., W.L., A.B., T.J.K., A.C., V.M.C-P., B.M.L., and R.S.D.;

Validation, K.Q., K.H., W.L., R.S., L.A.H., A.K.O., and S.S.M.;

Formal Analysis, K.Q., K.H., S.S.M., and R.S.D.;

Investigation, K.Q., K.H., S.S.M., W.L., R.S., A.K.O., and L.A.H.;

Resources, R.L., S.S., E.R.F., J.R.L., M.N., A.M., F.J.O., R.B.P., T.J.K., B.M.L., P.A.G., B.H.H., and R.S.D.;

Writing, B.H.H. and R.S.D.

## **DECLARATION OF INTERESTS**

The authors declare no competing interests.

#### FIGURE LEGENDS

Figure 1. Serologic and neutralizing responses in SARS-CoV-2 mRNA vaccinated CLL patients and healthy controls (HC).

(A and B) Comparison of SARS-CoV-2 vaccine-elicited spike (A) and RBD (B) ELISA IgG antibody titers in HC (n=30) and CLL (n=95) patients expressed as half-maximal effective concentrations (EC<sub>50</sub>).

(C and D) SARS-CoV-2 vaccine-elicited spike (C) and RBD (D) ELISA IgG antibody titers stratified by CLL disease status: treatment-naïve (Naïve) (n=45), on-therapy (On Tx) (n=34), off-therapy in clinical remission (CR) (n=9), and off therapy and relapsed or refractory (R/R) (n=7).

(E-G) Comparison of SARS-CoV-2 vaccine-elicited neutralizing antibody titers for HC (n=30) and CLL patients against (E) D614G (CLL; n=95) and (F) delta (CLL; n=93) spike variants expressed as the reciprocal half-maximal inhibitory dilution (ID<sub>50</sub>) as determined in an HIV-based pseudovirus neutralization assay or by (G) ACE2/RBD (Wuhan) binding inhibition (CLL; n=95) at a 1:25 dilution.

(H-J) SARS-CoV-2 vaccine elicited NAb titers for D614G (H) and delta (I) S variants and ACE2/RBD binding frequencies (J) stratified by CLL disease status.

Bars indicate the median with 95% CI. Dotted black lines indicate assay sensitivity cutoffs (EC $_{50}$  values of <100 by ELISA, ID $_{50}$  values of <20 in the neutralization assay, and >90% ACE2 binding in the RBD-inhibition assay).

P values were determined by the Mann-Whitney test (A-B, E-G) or Dunn's test of multiple comparisons following a Kruskal-Wallis test (C-D, H-J).

Figure 2. Impaired S peptide-restricted T cell subset responses and CD4<sup>+</sup> effector function, but retained CD8<sup>+</sup> T cell reactivity in CLL vaccinees.

- (A) Comparisons of S-specific T cell AIM response rates among CD4<sup>+</sup>, cTfh, and CD8<sup>+</sup> T cell subpopulations in SARS-CoV-2 mRNA vaccinated HC and CLL patients.
- (B) Quantitative comparisons of S-specific T cell AIM response frequencies for CD4<sup>+</sup>, cTfh, and CD8<sup>+</sup> T cells in SARS-CoV-2 mRNA vaccinated HC and CLL patients.
- (C) ICS response rates of S-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells from HC and CLL donors.

  Responders were defined as individuals with reactivity against at least one of five effector features (see text) upon peptide stimulation.
- (D) Quantitative comparisons of IFN<sub>γ</sub> production by CD4<sup>+</sup> and CD8<sup>+</sup>T cells.
- (E) Comparisons of CD4<sup>+</sup> and CD8<sup>+</sup>T cell effector responses calculated using combinatorial polyfunctionality analysis.<sup>39</sup>

Bars indicate the (A and C) mean or (B, D-E) median with 95% CI.

P values were determined by Fisher's exact test (A and C) or the Mann-Whitney test (B, D-E).

Figure 3. SARS-CoV-2 S-reactive CLL vaccinees lacking NAbs have pre-existing cross-reactivity with endemic HCoVs and the S2 subunit preferentially.

(A) Pie chart illustrating the distribution of SARS-CoV-2 S-specific seroreactivity and NAb generation (D614G), which define three different serologic profiles among all CLL patients.

(B and C) Comparisons of IgG EC<sub>50</sub> titers against SARS-CoV-2 (Wuhan) full-length S (B) or RBD (C) for all HC (n=30) versus S<sup>+</sup>NAb<sup>+</sup> (n=40) and S<sup>+</sup>NAb<sup>-</sup> (n=25) patients defined by the detection of endpoint titer Ab reactivity quantitated by ELISA.

(D) Comparisons of IgG EC<sub>50</sub> titers against the S (S1+S2) proteins of two pathogenic and four endemic HCoVs measured by ELISA from SARS-CoV-2 vaccinated HC (n=15) and CLL S<sup>+</sup>NAb<sup>-</sup> (n=25) samples.

(E and F) Comparisons of IgG EC<sub>50</sub> titers against SARS-CoV-2 S1 (E) or S2 (F) domains in vaccinated HC (n=15, from D) versus S<sup>+</sup>NAb<sup>-</sup> (n=19) CLL donors.

(G) Paired comparisons of log-transformed S1 versus S2 EC<sub>50</sub> titers for the HC and S<sup>+</sup>NAb<sup>-</sup>CLL donors analyzed in (E and F).

Bars indicate the median (B-F) with 95% CI. Dotted black lines indicate assay sensitivity cutoffs, specifically, EC<sub>50</sub> values of <100. P values were determined by Dunn's test of multiple comparisons following a Kruskal-Wallis test (B and C), the Mann-Whitney test (D-F), and with a two-tailed paired or unpaired t-test for differences within and between cohorts (G).

# Figure 4. NAb titers are higher in treatment-naive mRNA-2173 CLL vaccinees, but impaired in patients with features of clinical progression.

- (A) BNT162b2 (n=61) and mRNA-2173 (n=34) CLL vaccinees stratified by treatment-naive (Naive), active treatment (On Tx), clinical remission (CR), or relapsed/refractory (R/R) disease status.
- (B) Comparison of ID<sub>50</sub> neutralizing titers against the SARS-CoV-2 D614G variant for CLL patients classified by disease status (color coded as in A) and BNT162b2 or mRNA-2173 vaccine type.
- (C) Frequencies of four clinical features including Rai stage II-IV, absolute lymphocyte count (ALC; >5 x  $10^9$ /L), serum beta 2 microglobulin ( $\beta$ 2M; > 2.4 mg/L), and IVIg prophylaxis therapy, among treatment-naive CLL patients by BNT162b2 or mRNA-2173 vaccine type.

(D) Response rates for the generation of D614G NAbs by vaccine type in treatment-naive CLL

patients.

(E) Comparison of ID<sub>50</sub> titers against D614G for treatment-naive CLL patients by vaccine type.

(F) Frequencies of four clinical features between treatment-naive BNT162b2 vaccinees stratified

by NAb<sup>+</sup> (n=15) or NAb<sup>-</sup> (n=15) serologic status.

Bars indicate the mean (D) or median with 95% CI (B and E). P values were calculated with

Fisher's exact test (C-D, F) or the Mann-Whitney test (B and E).

Figure 5. Progressive alterations in naive CD4<sup>+</sup> and effector memory CD8<sup>+</sup> T cells

correlate with a loss of NAb responses in treatment-naive CLL vaccinees.

(A-F) PBMCs from vaccinated healthy controls ≥ 65 years old (n=7) and treatment-naive CLL

donors with the S<sup>+</sup>NAb<sup>+</sup> (n=11) or S<sup>+</sup>NAb<sup>-</sup> (n=9) serologic profiles were stained to enumerate the

frequencies of total CD3<sup>+</sup> (A), CD4<sup>+</sup> (B), and CD8<sup>+</sup> (C) T cells and CD4:CD8 ratios (D) as well as

CD4<sup>+</sup> (E) or CD8<sup>+</sup> (F) naïve (N), central memory (CM), effector memory (EM) and effector

memory CD45RA<sup>+</sup> (EMRA) T cell subpopulations.

Bars indicate the median with 95% CI. P values were determined by Dunn's test of multiple

comparisons following a Kruskal-Wallis test.

Figure 6. Progressive loss of adaptive immunity in treatment-naive CLL patients. Humoral

22

and cellular immune responses following SARS-CoV-2 mRNA vaccination uncovered three

distinct serologic profiles in CLL patients compared to healthy controls that reflect a graded

decline in adaptive immune function.

Table 1. Clinical and disease characteristics of healthy controls and CLL patients

Characteristic	Healthy controls (n=30)	CLL (n=95)
Age in years, median (IQR)	62 (44-69.8)	72 (64-77)
Age ≥65 y, n (%)	13 (43.3)	71 (74.7)
Sex, male, n (%)	16 (53.3)	47 (49.5)
σολ, παιο, π ( <i>γ</i> ο)	10 (00.0)	11 (10.0)
Rai Stage*, n (%)		
0-1	-	46 (88.5)
II-IV	-	6 (11.5)
Discoss/Tractment status in (0/)		
Disease/Treatment status, n (%) Treatment-naive		45 (47.4)
	-	45 (47.4)
Active-therapy	-	34 (35.8)
Off-therapy in remission	-	9 (9.5)
Off-therapy in relapse	-	7 (7.4)
Molecular and phenotypic biomarkers		
IGHV, mutated, n (%)	-	47/75 (62.7)
CD38 (≥20%), n (%)	-	23/90 (25.6)
FISH, n (%)		
Normal		10 (11.1)
del(13q)	-	48 (53.3)
Trisomy 12	_	15 (16.7)
del(11q)	-	10 (11.1)
del(17p)	-	7 (7.8)
dei(17p)	<u>-</u>	7 (7.0)
IVIg therapy, n (%)	-	25 (26.3)
		, ,
Laboratory parameters, median (IQR)		
Absolute lymphocyte count, (109/L)	-	6.8 (1.9-21.4)
β2-microglobulin, mg/L	-	2.2 (1.8-3.1)
IgM, mg/dL	-	28 (19-62.5)
IgG, mg/dL	-	713 (546.5-974)
IgA, mg/dL	-	105 (63.8-162.8)

IGHV, immune globulin heavy chain variable gene; FISH, fluorescence in situ hybridization

<sup>\*</sup>Determined for treatment-naïve and patients off therapy in relapse

#### **METHODS AND MATERIALS**

## **Human samples**

Blood samples were collected following institutional review board (IRB) approval by the University of Alabama at Birmingham (IRB #130821005 and 160125005) and written informed consent was obtained from all participants who were adults over age 18 and recruited between January and August 2021. Healthy controls (n=30) and CLL patients (n=95), who were diagnosed according to the International Workshop on Chronic Lymphocytic Leukemia guidelines,<sup>3</sup> were vaccinated in the community with the first and second doses of the Pfizer/BioNTech (BNT162b2) or Moderna (mRNA-1273) COVID-19 vaccines. Human peripheral blood mononuclear cells (PBMCs) and plasma samples were processed as previously described.<sup>22,57</sup> Details of the vaccinated CLL and healthy adult cohorts are listed in Tables 1 and S1. Samples were anonymized and coded so that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

To confirm that healthy donors and CLL patients had not been recently infected with SARS-CoV-2, blood samples were analyzed for the presence of nucleocapsid IgG antibodies in a clinical diagnostic laboratory (Abbott).<sup>58</sup>

Clinical characteristics of CLL patients were extracted by retrospective analysis of the electronic medical record and included demographics, disease and therapeutic history, Rai stage, laboratory data of the complete blood count, serum beta 2 microglobulin (β2M) and immunoglobulin levels, immunoglobulin heavy chain variable gene (*IGHV*) mutation status (delineated by germline identity of 98%), CD38 expression (≥20%), and cytogenetics analysis by fluorescence *in situ* hybridization (FISH).<sup>59</sup>

## SARS-CoV-2 S-protein and subunit ELISA

Plasma IgG binding antibodies to the entire SARS-CoV-2 spike (S) protein as well as receptor binding domain (RBD), and S1 and S2 proteins, were detected by enzyme-linked immunosorbent assay (ELISA) using recombinantly expressed (Wuhan-Hu-1 S-protein and RBD) and purchased (Wuhan-Hu-1 S1 and S2 proteins, ACROBiosystems) proteins as previously described.<sup>27, 60, 61</sup> Briefly, Costar high binding flat-bottom 96-well plates were coated with 300 ng per well of a pre-fusion stabilized (S-2P) S protein (residues 1-1138) (plasmid kindly provided by Philip Brouwer and Rogier W. Sanders, Department of Medical Microbiology, University of Amsterdam, Amsterdam, The Netherlands) or 400 ng of recombinantly expressed RBD (residues 419–541), S1 (residues 16-685) or S2 protein (residues 686-1213 with F817P, A892P, A899P, A942P, K986P and V987P substitutions for stabilization) in PBS overnight at 4°C and then incubated with blocking buffer (5% non-fat milk powder in PBS + 0.05% Tween 20) for 1 h at 37°C. Plasma samples were heat-inactivated at 56°C for 1 hour, 5-fold serially diluted in blocking buffer and then added to the plates for 1 h at 37°C. After five washes with PBS-T (PBS + 0.1% Tween 20), plates were incubated for 1 h at 37°C with horseradish peroxidase (HRP)-conjugated goat-anti-human IgG detection antibodies diluted 1:5,000 in blocking buffer. After five additional washes, 3, 3', 5, 5'-tetramethylbenzidine (TMB) substrate was added for color development for 10 min before the reaction was stopped with an equal volume of 1N H<sub>2</sub>SO<sub>4</sub>. Absorbance was read at 450 nm using a Synergy 4 spectrophotometer. The average OD<sub>450</sub> value from three background control wells (no plasma) was subtracted from the protein coated wells. In addition, the average OD<sub>450</sub> value (plus two standard deviations) of 28 pre-pandemic sera was subtracted from each plasma dilution. Midpoint (EC<sub>50</sub>) and endpoint titers were determined as described.<sup>22, 27</sup> Briefly, midpoint (EC<sub>50</sub>) titers were calculated by a nonlinear-regression fit of a 4-parameter sigmoid function to the corrected OD<sub>450</sub> values and the

logarithmic dilution factors (the lower plateau was set to 0; GraphPad Prism software). Endpoint titers were read from the fitted curve at a corrected OD<sub>450</sub> cutoff of 0.1.

### SARS-CoV-2 pseudovirus neutralization assay

Plasma samples of vaccinees were tested for neutralizing responses against the SARS-CoV-2 variants D614G<sup>28</sup> and B.1.617.2 (also termed Delta with mutations T19R, G142D, ΔΕ156, ΔΕ157, R158G, L452R, T478K, D614G, P681R, and D950N compared to Wuhan-Hu-1),<sup>29.30</sup> using an HIV-1 based pseudovirus assay as previously described.<sup>31</sup> Briefly, pseudovirus stocks were generated by co-transfecting spike expression plasmids (encoding proteins with a 19 amino acid cytoplasmic tail deletion) with an HIV-1 nanoluciferase encoding reporter backbone in HEK293T cells. Pseudovirus stocks were tittered to identify the appropriate infectious dose, incubated with five-fold serial dilutions of vaccinee plasma and then used to infect 1.5 x 10<sup>4</sup> 293T clone 13 cells expressing ACE2. Two days post-infection, cells were washed with PBS, lysed, and nanoluciferase activity was determined using a Nano-Glo® Luciferase Assay System. Luciferase activity in wells with virus and no plasma were set to 100%, and the dilution of plasma at which luminescence was reduced to 50% (Inhibitory Dose 50; ID<sub>50</sub>) was calculated as an average of two technical replicates. Each vaccinee plasma was analyzed under anonymized code on at least two occasions, with the geometric mean of all measurements reported. Values below a titer of 1:20 were treated as 20 when averaging.

#### ACE2/RBD binding inhibition assay

Plasma samples were analyzed with an ACE2/receptor binding domain (RBD) binding inhibition assay as previously described.<sup>22, 62</sup> High-binding 96-well plates (Corning #3690) were coated with 50 µl per well of recombinant RBD (Wuhan-Hu-1, RayBiotech) diluted at 1 µg/ml in PBS at

4°C overnight. The following day, plates were washed 3 times with PBS + 0.1% Tween 20 (PBST), and wells were blocked with 100 µl per well of 3% non-fat dry milk in PBST by incubation at room temperature for 1 h. After washing the blocked wells 3 times with PBST. either 50 µl of plasma serially diluted in 1% non-fat dry milk in PBST, or 1% non-fat dry milk in PBST alone as a no inhibition control, was added to wells, and incubated at room temperature for 2 h. Heat-inactivated plasma samples (56°C for 30 min) were initially diluted at 1:25, then serially diluted 2-fold for the assay to 1:400. After incubation, plates were washed 3 times with PBST, then 50 µl of recombinant human ACE2 (RayBiotech) diluted at 0.1 µg/ml in PBST was added to the wells. Plates were incubated at room temperature for 1 h, washed 4 times with PBST, and 50 µl of biotinylated goat anti-human ACE2 (R&D) diluted at 0.1 µg/ml in PBST was added to the wells. Plates were incubated at room temperature for 1 h, washed 4 times with PBST, and then 50 µl of HRP-conjugated streptavidin (Southern Biotech) (1:2,000 in PBST) was added to the wells, and incubated at room temperature for 30 min. Plates were washed 5 times with PBST, developed with 50 µl per well of 3,3',5,5'-tetramethylbenzidine TMB substrate (Biolegend) at room temperature for 8 min, and the reaction was stopped by addition of 50 µl of 1N H<sub>2</sub>SO<sub>4</sub>. The OD was measured at 450 nm with a SPECTROstar omega (BMG Labtech) microplate reader. ACE2 binding was expressed as a percentage of OD values relative to the OD<sub>450</sub> value of a no inhibition control. Binding values of <90% at a 1:25 dilution of plasma were used to calculate inhibitory activity. The upper limit of the assay was 100%.

### Human Coronavirus (HCoV) spike protein ELISA

High-binding 96-well plates (Corning #3690) were coated at 4°C overnight with 50 μl per well of the following recombinant Spike (S1+S2) proteins: SARS-CoV, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63, or HCoV-229E (all from Sino Biological) diluted at 2 μg/ml in PBS. The following day, plates were washed 3 times with 0.1% Tween 20 in PBS (PBST). A blocking

solution of 100 µl per well of 3% non-fat dry milk in PBST was added and incubated at room temperature for 1 h before washing plates 3 times with PBST. Plasma samples were heatinactivated at 56°C for 30 min and initially diluted at 1:20, then serially diluted 5-fold in 1% nonfat dry milk in PBST before adding 50 µl per well, and incubating at room temperature for 2 h. Plates were then washed 4 times with PBST, and 50 µl per well of horseradish peroxidase (HRP) conjugated goat anti-human IgG (Southern Biotech #2045-05) diluted at 1:6,000 in PBST was added to the wells and incubated at room temperature for 1 h to measure Spike protein IgG Ab responses. Plates were washed 5 times with PBST, developed with 50 µl per well of HRP substrate 3, 3', 5, 5' tetramethyl benzidine (TMB, Biolegend) at room temperature for 10 min. The reaction was stopped by addition of 50 µl per well of 1N H<sub>2</sub>SO<sub>4</sub>. The optical density (OD) was measured at 450 nm with an Epoch microplate spectrophotometer (BioTek). OD<sub>450</sub> values of blank wells, which were Spike protein-coated wells without plasma, were subtracted from OD<sub>450</sub> values of sample wells, and EC<sub>50</sub> values were determined by a nonlinear-regression fit of a 4-parameter sigmoid function with the corrected OD<sub>450</sub> values and the dilution factors.

## Flow cytometry-based T cell immunophenotyping, AIM, and ICS analyses

For immunophenotyping, cryopreserved PBMCs were thawed and washed with FACS wash buffer (2% FBS in PBS). Cells were then stained with CCR7-PerCP5.5, incubated at 37°C for 20 min, and then stained with the following antibodies: CD3-Alexa780, CD4-BV711, CD8-FITC, CD45RA-BV510, CD19-BUV563, and LIVE/DEAD-UV. After incubation at 4°C for 30 min, cells were washed twice with FACS wash buffer (2% FBS in PBS) and fixed in a 4% formalin solution. Events were collected on a BD FACSymphony A3 instrument within 24 h and analyzed using FlowJo software (v10).

For activation-induced marker staining (AIM), antigen-specific T cells were measured as previously described. FPBMCs were stimulated with SARS-CoV-2 N and S protein peptide pools (BEI Resources) at an individual peptide concentration of 1 µg/ml in the presence of costimulatory anti-CD28 and anti-CD49d antibodies (BD Pharmingen). Cell aliquots from each sample were stimulated with equal amounts of dimethyl sulfoxide (DMSO) as a negative control and staphylococcal enterotoxin B (SEB) as a positive control. After incubation at 37°C for 18 h, cells were washed and stained with the following antibodies: CD4-BV711, CD3-Alexa780, CD8-FITC, CD19-BUV563, OX40-PECy7, PDL1-PE, CXCR5-BV421, PD1-BV785, CD137-BV650, CD69-BUV737, and LIVE/DEAD-UV. Cells were then washed and fixed in 4% formalin. Events were collected on a BD FACSymphony A3 instrument and analyzed using FlowJo software (v10).

Intra-cellular staining (ICS) experiments were performed in parallel with the AIM analysis as previously described.<sup>57</sup> CD107a-FITC was added with the co-stimulatory antibody mix. Cells were incubated for a total of 12 h in total. Staining was conducted in three steps: 1) Surface marker staining for 30 min at 4°C with LIVE/DEAD-UV, CD3-Alexa780, CD4-BV711, CD8-V500, CD14-PercpCy5.5, and CD19-BUV563; 2) Permeabilization with CytoFix/CytoPerm solution (BD Biosciences) for 20 min at 4°C; and 3) ICS for 30 min at 4°C with IFNγ-Alexa700, TNFα-PECy7, IL2-APC, GranzymeB-V450, and Perforin-PE. Finally, cells were washed twice and fixed in 4% formalin. Events were collected on a BD FACSymphony A3 instrument and analyzed using FlowJo software (v10). For both AIM and ICS, positive responses were determined by comparison to an unstimulated control with a threshold above at least three times and higher statistical significance by calculation of Chi-square analysis with Yates' correction (p value < 0.05). Combinatorial polyfunctionality analysis (COMPASS) of antigen-specific T-cells was calculated as previously described.<sup>39</sup>

## Statistical analysis

Data were analyzed in R v4.0.5 and GraphPad Prism version 9.0 software. Statistical details of the experiments are provided in the respective figure legends and tables. Associations between serological or cellular responses with dichotomous clinical data were analyzed using Fisher's exact test and with continuous clinical variables using the Mann-Whitney test. P values were adjusted for multiple comparisons of serologic, cellular, and clinical data using the Benjamini–Hochberg procedure for false discovery rate. For comparisons of more than two categories, P values were determined by Dunn's test of multiple comparisons following a Kruskal-Wallis test. Firth logistic regression was used to examine the association of serologic or cellular responses with clinical variables. GraphPad Prism version 9.0 software was used to plot these analyses. Significance was determined as p-value < 0.05 unless otherwise stated.

#### **REFERENCES**

- 1. SEER (2014-2018). Surveillance, Epidemiology, and End Results (SEER) Program. doi:https://seer.cancer.gov/statfacts/html/clyl.html.
- 2. Forconi, F., and Moss, P. (2015). Perturbation of the normal immune system in patients with CLL. Blood *126*, 573-581. doi:10.1182/blood-2015-03-567388.
- 3. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N. et al. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood *131*, 2745-2760. doi:10.1182/blood-2017-09-806398.
- 4. Sun, C., Gao, J., Couzens, L., Tian, X., Farooqui, M.Z., Eichelberger, M.C., and Wiestner, A. (2016). Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. JAMA Oncol *2*, 1656-1657. doi:10.1001/jamaoncol.2016.2437.
- 5. Douglas, A.P., Trubiano, J.A., Barr, I., Leung, V., Slavin, M.A., and Tam, C.S. (2017). Ibrutinib may impair serological responses to influenza vaccination. Haematologica *102*, e397-e399. doi:10.3324/haematol.2017.164285.
- 6. Svensson, T., Kattstrom, M., Hammarlund, Y., Roth, D., Andersson, P.O., Svensson, M., Nilsson, I., Rombo, L., Cherif, H., and Kimby, E. (2018). Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine *36*, 3701-3707. doi:10.1016/j.vaccine.2018.05.012.
- 7. Mauro, F.R., Giannarelli, D., Galluzzo, C.M., Vitale, C., Visentin, A., Riemma, C., Rosati, S., Porrazzo, M., Pepe, S., Coscia, M. et al. (2021). Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia *35*, 737-746. doi:10.1038/s41375-020-0884-z.
- 8. Pleyer, C., Ali, M.A., Cohen, J.I., Tian, X., Soto, S., Ahn, I.E., Gaglione, E.M., Nierman, P., Marti, G.E., Hesdorffer, C. et al. (2021). Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood *137*, 185-189. doi:10.1182/blood.2020008758.
- 9. Na, I.K., Buckland, M., Agostini, C., Edgar, J.D.M., Friman, V., Michallet, M., Sanchez-Ramon, S., Scheibenbogen, C., and Quinti, I. (2019). Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur. J. Haematol. *102*, 447-456. doi:10.1111/ejh.13223.
- 10. Forni, D., Cagliani, R., Pozzoli, U., Mozzi, A., Arrigoni, F., De Gioia, L., Clerici, M., and Sironi, M. (2022). Dating the Emergence of Human Endemic Coronaviruses. Viruses *14*. doi:10.3390/v14051095.
- 11. Edridge, A.W.D., Kaczorowska, J., Hoste, A.C.R., Bakker, M., Klein, M., Loens, K., Jebbink, M.F., Matser, A., Kinsella, C.M., Rueda, P. et al. (2020). Seasonal coronavirus protective immunity is short-lasting. Nat. Med. *26*, 1691-1693. doi:10.1038/s41591-020-1083-1.

- 12. Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. *20*, 533-534. doi:10.1016/S1473-3099(20)30120-1.
- 13. Fung, M., and Babik, J.M. (2021). COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. 72, 340-350. doi:10.1093/cid/ciaa863.
- 14. Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C., and Di Napoli, R. (2022). Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls, (StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.).
- 15. Mato, A.R., Roeker, L.E., Lamanna, N., Allan, J.N., Leslie, L., Pagel, J.M., Patel, K., Osterborg, A., Wojenski, D., Kamdar, M. et al. (2020). Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood *136*, 1134-1143. doi:10.1182/blood.2020006965.
- 16. Chatzikonstantinou, T., Kapetanakis, A., Scarfo, L., Karakatsoulis, G., Allsup, D., Cabrero, A.A., Andres, M., Antic, D., Baile, M., Baliakas, P. et al. (2021). COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia *35*, 3444-3454. doi:10.1038/s41375-021-01450-8.
- 17. Niemann, C.U., da Cunha-Bang, C., Helleberg, M., Ostrowski, S.R., and Brieghel, C. (2022). Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. Blood *140*, 445-450. doi:10.1182/blood.2022016147.
- 18. Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell *181*, 281-292 e286. doi:10.1016/j.cell.2020.02.058.
- 19. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A. et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell *181*, 271-280 e278. doi:10.1016/j.cell.2020.02.052.
- Avanzato, V.A., Matson, M.J., Seifert, S.N., Pryce, R., Williamson, B.N., Anzick, S.L., Barbian, K., Judson, S.D., Fischer, E.R., Martens, C. et al. (2020). Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 183, 1901-1912 e1909. doi:10.1016/j.cell.2020.10.049.
- 21. Jiang, S., Zhang, X., Yang, Y., Hotez, P.J., and Du, L. (2020). Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng *4*, 1134-1139. doi:10.1038/s41551-020-00660-2.
- 22. Honjo, K., Russell, R.M., Li, R., Liu, W., Stoltz, R., Tabengwa, E.M., Hua, Y., Prichard, L., Kornbrust, A.N., Sterrett, S. et al. (2021). Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Rep Med 2, 100164. doi:10.1016/j.xcrm.2020.100164.
- 23. Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C.R., Martins, K., Jayashankar, L. et al. (2022). Immune correlates

- analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science *375*, 43-50. doi:10.1126/science.abm3425.
- 24. Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., Morales, M., Ziv, T., Shorer Arbel, Y., Scarfo, L. et al. (2021). Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood *137*, 3165-3173. doi:10.1182/blood.2021011568.
- 25. Greenberger, L.M., Saltzman, L.A., Senefeld, J.W., Johnson, P.W., DeGennaro, L.J., and Nichols, G.L. (2021). Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell *39*, 1031-1033. doi:10.1016/j.ccell.2021.07.012.
- 26. Blixt, L., Wullimann, D., Aleman, S., Lundin, J., Chen, P., Gao, Y., Cuapio, A., Akber, M., Lange, J., Rivera-Ballesteros, O. et al. (2022). T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. Haematologica 107, 1000-1003. doi:10.3324/haematol.2021.280300.
- 27. Liu, W., Russell, R.M., Bibollet-Ruche, F., Skelly, A.N., Sherrill-Mix, S., Freeman, D.A., Stoltz, R., Lindemuth, E., Lee, F.H., Sterrett, S. et al. (2021). Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerg. Infect. Dis. 27, 2454-2458. doi:10.3201/eid2709.211042.
- 28. Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E.E., Bhattacharya, T., Foley, B. et al. (2020). Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell *182*, 812-827 e819. doi:10.1016/j.cell.2020.06.043.
- 29. Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A.J., Zhao, Y. et al. (2021). Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell *184*, 4220-4236 e4213. doi:10.1016/j.cell.2021.06.020.
- 30. Wang, L., Zhou, T., Zhang, Y., Yang, E.S., Schramm, C.A., Shi, W., Pegu, A., Oloniniyi, O.K., Henry, A.R., Darko, S. et al. (2021). Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science *373*. doi:10.1126/science.abh1766.
- 31. Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.H., Michailidis, E., Lorenzi, J.C.C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C. et al. (2020). Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. *217*. doi:10.1084/jem.20201181.
- 32. Parry, H., McIlroy, G., Bruton, R., Damery, S., Tyson, G., Logan, N., Davis, C., Willett, B., Zuo, J., Ali, M. et al. (2022). Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. J. Hematol. Oncol. *15*, 3. doi:10.1186/s13045-021-01219-7.
- 33. Platsoucas, C.D., Galinski, M., Kempin, S., Reich, L., Clarkson, B., and Good, R.A. (1982). Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. J. Immunol. *129*, 2305-2312.

- 34. Peller, S., and Kaufman, S. (1991). Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: correlation with disease stage. Blood *78*, 1569-1573.
- 35. Schreeder, D.M., Pan, J., Li, F.J., Vivier, E., and Davis, R.S. (2008). FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia. Eur. J. Immunol. 38, 3159-3166. doi:10.1002/eji.200838516.
- 36. Riches, J.C., Davies, J.K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A.G., and Gribben, J.G. (2013). T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood *121*, 1612-1621. doi:10.1182/blood-2012-09-457531.
- 37. Tarke, A., Sidney, J., Kidd, C.K., Dan, J.M., Ramirez, S.I., Yu, E.D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P. et al. (2021). Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med 2, 100204. doi:10.1016/j.xcrm.2021.100204.
- 38. Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S.I., Dan, J.M., Burger, Z.C., Rawlings, S.A., Smith, D.M., Phillips, E. et al. (2020). Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science *370*, 89-94. doi:10.1126/science.abd3871.
- 39. Lin, L., Finak, G., Ushey, K., Seshadri, C., Hawn, T.R., Frahm, N., Scriba, T.J., Mahomed, H., Hanekom, W., Bart, P.A. et al. (2015). COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. *33*, 610-616. doi:10.1038/nbt.3187.
- 40. Cyster, J.G., and Allen, C.D.C. (2019). B Cell Responses: Cell Interaction Dynamics and Decisions. Cell *177*, 524-540. doi:10.1016/j.cell.2019.03.016.
- 41. Mesin, L., Ersching, J., and Victora, G.D. (2016). Germinal Center B Cell Dynamics. Immunity 45, 471-482. doi:10.1016/j.immuni.2016.09.001.
- de Bourcy, C.F., Angel, C.J., Vollmers, C., Dekker, C.L., Davis, M.M., and Quake, S.R. (2017). Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging. Proc. Natl. Acad. Sci. U. S. A. *114*, 1105-1110. doi:10.1073/pnas.1617959114.
- 43. Henry, C., Zheng, N.Y., Huang, M., Cabanov, A., Rojas, K.T., Kaur, K., Andrews, S.F., Palm, A.E., Chen, Y.Q., Li, Y. et al. (2019). Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. Cell Host Microbe *25*, 357-366 e356. doi:10.1016/j.chom.2019.01.002.
- 44. Francis, T. (1960). On the doctrine of original antigenic sin. Proceedings of the American Philosophical Society *104*, 572-578.
- 45. Whitaker, J.A., Parikh, S.A., Shanafelt, T.D., Kay, N.E., Kennedy, R.B., Grill, D.E., Goergen, K.M., Call, T.G., Kendarian, S.S., Ding, W. et al. (2021). The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell

- lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine 39, 1122-1130. doi:10.1016/j.vaccine.2021.01.001.
- 46. Herishanu, Y., Rahav, G., Levi, S., Braester, A., Itchaki, G., Bairey, O., Dally, N., Shvidel, L., Ziv-Baran, T., Polliack, A. et al. (2022). Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood *139*, 678-685. doi:10.1182/blood.2021014085.
- 47. Greenberger, L.M., Saltzman, L.A., Gruenbaum, L.M., Xu, J., Reddy, S.T., Senefeld, J.W., Johnson, P.W., Fields, P.A., Sanders, C., DeGennaro, L.J. et al. (2022). Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies. Blood Cancer Discov 3, 481-489. doi:10.1158/2643-3230.BCD-22-0077.
- 48. Farcet, M.R., Karbiener, M., Knotzer, S., Schwaiger, J., and Kreil, T.R. (2022). Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe. J. Infect. Dis. 226, 1396-1400. doi:10.1093/infdis/jiac358.
- 49. Bruel, T., Hadjadj, J., Maes, P., Planas, D., Seve, A., Staropoli, I., Guivel-Benhassine, F., Porrot, F., Bolland, W.H., Nguyen, Y. et al. (2022). Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. 28, 1297-1302. doi:10.1038/s41591-022-01792-5.
- 50. Sacco, M.D., Hu, Y., Gongora, M.V., Meilleur, F., Kemp, M.T., Zhang, X., Wang, J., and Chen, Y. (2022). The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 32, 498-500. doi:10.1038/s41422-022-00640-y.
- 51. G Doukas, P., St Pierre, F., Boyer, J., Nieves, M., and Ma, S. (2022). CLO22-043: Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Large, Single-Center Observational Study. J. Natl. Compr. Canc. Netw. 20, CLO22-043-CLO022-043. doi:10.6004/jnccn.2021.7248.
- 52. Mitchell, J., Connolly, C.M., Chiang, T.P., Alejo, J.L., Werbel, W.A., Segev, D.L., and Massie, A.B. (2022). Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients. JAMA Netw Open *5*, e2211897. doi:10.1001/jamanetworkopen.2022.11897.
- 53. Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B. et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. *384*, 403-416. doi:10.1056/NEJMoa2035389.
- 54. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez Marc, G., Moreira, E.D., Zerbini, C. et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603-2615. doi:10.1056/NEJMoa2034577.

- 55. Anderson, E.J., Rouphael, N.G., Widge, A.T., Jackson, L.A., Roberts, P.C., Makhene, M., Chappell, J.D., Denison, M.R., Stevens, L.J., Pruijssers, A.J. et al. (2020). Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 383, 2427-2438. doi:10.1056/NEJMoa2028436.
- 56. Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., and Zhou, Q. (2021). A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Cent Sci 7, 512-533. doi:10.1021/acscentsci.1c00120.
- 57. Boppana, S., Qin, K., Files, J.K., Russell, R.M., Stoltz, R., Bibollet-Ruche, F., Bansal, A., Erdmann, N., Hahn, B.H., and Goepfert, P.A. (2021). SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathog. *17*, e1009761. doi:10.1371/journal.ppat.1009761.
- 58. Bryan, A., Pepper, G., Wener, M.H., Fink, S.L., Morishima, C., Chaudhary, A., Jerome, K.R., Mathias, P.C., and Greninger, A.L. (2020). Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J. Clin. Microbiol. *58*, JCM.00941-00920. doi:10.1128/JCM.00941-20.
- 59. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M., and Lichter, P. (2000). Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. *343*, 1910-1916. doi:10.1056/NEJM200012283432602.
- 60. Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S., Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G. et al. (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643-650. doi:10.1126/science.abc5902.
- 61. Ketas, T.J., Chaturbhuj, D., Portillo, V.M.C., Francomano, E., Golden, E., Chandrasekhar, S., Debnath, G., Diaz-Tapia, R., Yasmeen, A., Kramer, K.D. et al. (2021). Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun *6*, 116-134. doi:10.20411/pai.v6i1.441.
- 62. Kumar, G., Sterrett, S., Hall, L., Tabengwa, E., Honjo, K., Larimer, M., Davis, R.S., Goepfert, P.A., and Larimer, B.M. (2022). Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies. Protein Eng Des Sel *35*, gzab033. doi:10.1093/protein/gzab033.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure S1



## Figure S1. CLL patients have altered total CD4<sup>+</sup> and CD8<sup>+</sup> T cell and subpopulation frequencies, Related to Figures 2 & 5.

Immunophenotyping of PBMCs from vaccinated HC (n=21) and CLL (n=36) donors.

- (A-D) Quantitative comparisons of total CD3<sup>+</sup> (A), CD4<sup>+</sup> (B), and CD8<sup>+</sup> (C) T cell frequencies and CD4:CD8 ratios (D).
- (E-F) Representative flow cytometry plots and quantitative comparisons of naïve (N), central memory (CM), effector memory (EM) and effector memory CD45RA+ (EMRA) CD4+ (E) and CD8+ (F) subpopulation frequencies defined by the CCR7 and CD45RA surface markers in HC and CLL donors.

Bars indicate the median with 95% CI. P values were determined by the Mann-Whitney test.

### Figure S2





Figure S2. Flow cytometry gating strategies for measuring T cell responses from a CLL donor after S peptide pool stimulation, Related to Figure 2.

- (A) Gating strategy to examine activation-induced markers (AIM) by CD4+, cTfh, and CD8+ T cells.
- (B) Gating strategy to examine CD4<sup>+</sup> and CD8<sup>+</sup> T cell effector function by intra-cellular staining (ICS).

Figure S3



# Figure S3. NAb titers against the Delta variant are higher in total and treatment-naïve mRNA-2173 CLL vaccinees, but lower in patients with clinical progression, Related to Figure 4.

- (A) Comparison of  $ID_{50}$  neutralizing titers against the SARS-CoV-2 Delta variant for CLL patients classified by BNT162b2 (n=60) or mRNA-2173 (n=33) vaccine type.
- (B) Response rates for the generation of Delta NAbs by vaccine type in treatment-naive CLL patients.
- (C) Comparison of  $ID_{50}$  titers against Delta for treatment-naive CLL patients by BNT162b2 (n=30) or mRNA-2173 (n=15) vaccine type.
- (D) Frequencies of four clinical features between treatment-naive BNT162b2 vaccinees stratified by Delta NAb<sup>+</sup> (n=13) or NAb<sup>-</sup> (n=17) serologic status.

Bars indicate the median with 95% CI (A and C) or mean (B). P values were calculated with the Mann-Whitney test (A and C) or Fisher's exact test (B and D).

Table 51. Disease characteristics and features of Sark Co. 2022. The copyright holder for this

Table S1. D	isease characteristics preprinc <sub>lin</sub>	XIA BLEDI	ISARS-COV-2	Vaccinated	CLL subjects,	Relate	d to Fi	gures 1	2 1 2 8 4 an	a 19 a Tal	2228364 11hor/func	5; thi	s vers <del>ho ha</del>	ion p	osted L <del>ated m</del>	Jecemi <del>edR xiv</del>	per 20, <del>la licer</del>	2022. I se to di	he cop	yrıgr e or	nt holder fo renrintana	r this <del>emetrity</del>
	proprincin	cal Features •••	l liot v	Prognes	suc majke e	<b>61 1</b> (	Syloger	netigs t	SY MON	, ui	att 101/1011t	Anti-C	D20 Tx	Herry-paner B1	∏ype⊂iii ΓKiTx		la mocif	g Isotypes (mg	/L)	іс рі	Opinivaceine	peakines only.
						It is	ma	de a	availa	abl	e u <b>rid</b> er a	CC-E	3Y 4.0	) Inter	rnation	al licen	se .					
CLL Sample	Rai Stage Naïve or Off Tx R/R (II-IV=1)	ALC (>5,000 [10 <sup>9</sup> /L] =1)	β2M (≤2.4 mg/L=1)	IGHV (MT=1)	CD38 (>20%=1)	13q	tri12	WNL	11q	17p	(Y=1)	<12M	≥12M	Alone	Comboa	Active Tx	IgA (≥60=1)	lgG (≥650=1)	lgM (≥40=1)	IVIg Tx	Type (Pfizer=1; Moderna=0)	Months from #2 VAX (≤1/2/≥3)
1 CLLV1	0	0	0	0	0	1					1	1			1					1	1	1
2 CLLV2 3 CLLV3	U	0	1	0	1 0	1	1				1		1	1			1	0	0	0	1	1
4 CLLV4 5 CLLV5		0	1	0 ND	0				1	1	1		1		1	I/BTKi				1	0	1
6 CLLV6		1	1	ND ND	0	1				'	1		'	1	'					1	1	2
7 CLLV7	0	0	0	ND 1	1		1				1		1		1	P/BTKi				1	1	2
9 CLLV8 CLLV9	U	0	ND	1	0	1					1		1							1	1	1
0 CLLV10 1 CLLV11	0	1	1	ND 0	1	1					0	4					1	1	1 0	0	0	1
2 CLLV11	1	1	ND	1	0	1	'				0						'	'		1	1	1
3 CLLV13 4 CLLV14		1	1	0	1		1		1		1		1	1		P	0	0	0	0	1	2
5 CLLV15	0	1	ND	1	0	1	'				0		'			-		'	U	1	0	i
6 CLLV16 7 CLLV17		0	1	ND 0	ND 1	ND	1 ND	ND	ND	ND	1	1	1	4	1		1	1	1	0	0	1
8 CLLV18		0	1	1	0	1	ND	ND	ND	IND	1	1	'	'	1	A/BTKi/V	1	1	0	0	1	2
9 CLLV19 CLLV20	0	1	0	1	0	ND	ND	ND	ND	ND	0						0	0	0	0	0	1
0 CLLV20 CLLV21	1	1	0	1	1	1		1			0						1	0	0	0	1	2
22 CLLV22	0	0	1	0	0	1					1	1								1	1	2
23 CLLV23 24 CLLV24	0	0	1	1 0	0			1			U 1	1					1	1	1	0	0	1
25 CLLV25		0	Ó	ND	0	1					1		1			С	0	0	1	0	1	2
26 CLLV26 CLLV27	0	0	1	ND 1	0 1	1	1				1 0		1	1			0	0 1	0 1	0	0	1 2
28 CLLV28	ŏ	1	ND	1	0	Ĭ .		1			ō						1	0	0	0	0	2
9 CLLV29 CLLV30	1	0	0	0	0	1				1	1			1			1	0	0	0	1	2
CLLV31	Ó	1	ó	1	0	1					1						· '	'	-	1	1	1
3 CLLV32 CLLV33	0	0	1	1	0	1					0						1	1	0	0	1	3
4 CLLV34	0	1	0	1	0	l '		1			0						1	1	0	0	1	1
55 CLLV35 CLLV36		0	1	ND	0		1				1		1				1	1	1	0	1	1
66 CLLV36 CLLV37	U	0	0	0	0	'				1	1		1				1	1	1	0	1	1
SE CLLV38	0	1	1	1	0	١.				1	0						1	1	1	0	1	2
9 CLLV39 CLLV40	1	1	1	1	0	1					1	1	1		1		0	0	0	0	1	2
11 CLLV41		0	0	0	1					1	1	1								1	0	1
12 CLLV42 13 CLLV43	-	0	1	0 ND	0	1			1		1		1	1			1	1	1	1	1	2
14 CLLV44	0	0	1	ND	ND	ND	ND	ND	ND	ND	0			-			1	1	0	0	1	2
15 CLLV45 16 CLLV46	0	0	0	0	0	1					1	1				A/PI3Ki/V	1	0	0	0	0	2
7 CLLV47		0	1	ND	ND		1				1		1				1	1	1	0	1	2
18 CLLV48 19 CLLV49	0	1	0	1	0	1			1		0		1				1	1 0	1	0	0	3 1
60 CLLV50	Ŭ	1	ND	1	o o	1					1	1	·					•		1	1	2
61 CLLV51 62 CLLV52		0	0	0	1	1					1	1					0	0	0	0	0	1
32 CLLV52 CLLV53	U	0	1	ND	1	ND	ND	ND	ND	ND	1		1				'	'	U	1	1	3
CLLV54	0	1	0	1	0	1					1		1				_	0	0	1	0	2
55 CLLV55 66 CLLV56	0	0	ND 1	ND	0	1		1			0						1	1	1	0	0	3
7 CLLV57	0	1	1	1	0	1					0						1	0	0	0	1	2
58 CLLV58 59 CLLV59	0	1	1 ND	1	0			1		1	1						0	0	0	0	1	1
CLLV60	1	1	0	1	Ō		1				0									1	1	3
61 CLLV61 62 CLLV62	0	0	0	ND 1	0			1	1		1 0			1			1	1	1	0	1 0	3
CLLV63	ō	0	0	ND	1	ND	ND	ND	ND	ND	0	,					0	1	0	0	0	3
64 CLLV64 65 CLLV65	0	0	1	0	1 0	1					1 0	1			1		1	1 0	1	0	1	1
66 CLLV66	1	0	0	0	1	Ė	1				1	1			1					1	0	3
67 CLLV67 68 CLLV68	0	0	ND 0	1 0	0	1			1		1 0		1				0	1	1 0	0	1 1	3
CLLV69	ŏ	1	1	1	0	1					ō						0	1	0	0	0	3
0 CLLV70 1 CLLV71	-	1 n	0	1 0	0	1			1		1		1			P V	1	1	0	0	1 0	3
2 CLLV72	1	ő	1	ND	0			1	'		i		1			*	1	1	1	0	0	3
'3 CLLV73 '4 CLLV74	-	0	0 ND	0	0		1			1	1		1	1	4	BTKi/V				1	1	3
'5 CLLV75		1	ND	1	0	1				'	1	1			'	BIKIV	0	0	0	0	0	3
'6 CLLV76	0	1 0	1 0	1 0	0	1			4		0		4				1	1	1	0	0	3
77 CLLV77 78 CLLV78	0	1	0	1	1 ND	1			1		0		1			L	1	1	0	1 0	1	3
<b>9</b> CLLV79	0	1	ND	1	0	1					0		,				1	1	0	0	1	3
0 CLLV80 CLLV81	0	1 0	0	0	0	1			1		1		1 1	1			1	0	0	0	0	2
CLLV82	0	1	1	1	0	1					0	,					1	1	0	0	0	3
3 CLLV83 CLLV84	0	0	ND 1	ND 1	0 1	1		1			1 0	1			1		1	0 1	0	0	0	2
5 CLLV85	0	1	1	1	ND	1					0						1	1	0	0	1	2
66 CLLV86 CLLV87	0	1	1 0	1	1 0		1 1				0						1	0	1	0	1	3
8 CLLV88	0	1	1	0	1				1		0						1	1	1	0	1	2
0 CLLV89 CLLV90	0	0	ND 1	ND 1	0	1					1 0		1				1	1 0	1	0	1	3
CLLV90 CLLV91	0	0	1	ND	0	l '	1				0						1	1	0	0	1	3
CLLV92		0	0	0	0	4	1				1			1			1	0	0	0	1	3
03 CLLV93 04 CLLV94	0	1	0	1	0 1	1					0						1	1	0	0	0	3
5 CLLV95	0	1	1	ND	0	1					Ō						1	0	0	0	1	3
30		mont with anti CI			anacified in the																	

<sup>&</sup>lt;sup>a</sup>Combo indicates concomitant treatment with anti-CD20/BTKi unless otherwise specified in the Other Tx column

Abbreviations: R/R, relapsed refractory; ALC, absolute lymphocyte count; p2M, Beta 2 microglobulin; ND, no data; KGHV, immunoglobulin heavy chain variable region gene; MT, mutated; FISH, fluorescence in situ hybridization; WNL, within normal limits; Tx, treatment; BTKi, Bruton's tyrosine kinase inhibitor; I, imatinib; P, prednisone; A, anti-CD20; V, venetoclax; C, cyclosporine; P/3Ki, Phosphoinositide 3-kinase inhibitor; I, lenalidomide; IV/g, intravenous immunoglobulin; Pfizer-BioNTech, BNT162b2; Moderna, mRNA-2173

Values of "1" indicate the presence and "0" the absence of a variable. For values left blank, data are not applicable.

Table S2. Binding and non-adRxiv or reprint doin https://doi.org/10.1101/2022.12.10.12.22.836.45...this version posted December 20, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Binding antibodies

RBD/ACE2 ID S1 S2 RBD/ACE2 D614G Delta
Endpoint isc Macdeo aVallable Under a log of the control of the contr Endpoint EC<sub>50</sub> EC<sub>50</sub> Endpoint EC<sub>50</sub> 66220 1829 1492 10506 14550 13180 100315 207896 Male 46347 Healthy Healthy Healthy Healthy Healthy Healthy 2754 24253 38100 3473 4339 4722 12452 Female Female Female Male Male 3454 44369 48276 9754 5780 239875 >312500 23760 25047 651 2711 125 319 1959 1272 20.5 19.9 17.6 3.5 48.6 0.6 Female Female Male 61522 69473 14123 9103 132297 2390 8471 25922 103877 1220 1263 23979 Health 2247 26478 230 11830 1119 15479 83 <20 2661 77 339 147 511 1390 479 1288 353 533 709 677 320 251 1295 310 39 71 514 Health Female 108316 >312500 26151 >312500 54808 >312500 132888 6398 Health Health Female Male 10050 13974 151027 177209 2527 31974 53091 4976 4510 13278 54050 20.3 18.5 28.7 24.9 5.5 1.9 4.6 2.2 8.7 3.5 4.6 398 1046 82832 53091 26567 112835 86869 201615 184510 91555 87278 Health Female
Male
Female
Female
Female
Female
Male
Male
Male
Male
Male 15011 2439 4678 4069 12719 16553 5864 6343 5186 61199 423 1437 2156 471 1045 427 691 964 1221 Healthy Healthy Healthy Healthy Healthy Healthy Healthy 15911 15433 16199 34574 37503 18933 15276 250229 266151 262987 >312500 >312500 >312500 225339 18 19 20 21 22 23 24 25 26 27 28 29 30 HC18 HC20 HC21 28325 >312500 9890 120823 160705 12777 37411 >312500 HC22 Healthy Healthy Healthy Healthy Healthy Healthy Healthy Healthy 9945 8790 46399 15586 2712 10379 42858 80034 127507 3040 2648 44720 34505 14.4 22.3 11.6 13.5 61.8 52.3 3.4 72 49 64.5 442 280 1528 368 42 114 457 51 85 Male
Female
Male
Male
Male
Male
Female
Male
Male
Female
Male
Male HC24 HC25 HC26 HC27 HC28 HC29 127507 >312500 225216 45027 94070 >312500 34505 >312500 89684 15080 17079 73382 13108 13452 27919 5616 791 1439 3682 763 1669 53 140 <20 2230 4425 27529 HC30 96677 15125 Health Male 1480 402 7702 ND ND ND ND On.Tx Tx.naïve On.Tx Off.Tx.CR CLLV1 CLLV2 CLLV3 Male Male <100 10814 438 <100 2886 159 433 <100 38114 559 10349 >90 49.8 >90 59.9  $\begin{array}{c} X D D & 267 \\ X D$ ND ND 6362 ND 5001 ND ND ND ND ND ND ND ND ND <200</p>
308
<200</p>
<20</p>
<200</p>
<200</p>
<200</p>
<20</p>
<20</p> <20</li>
 <100 116098 Female 13445 Female CLLV4 2097 19504 Off.Tx.CR On.Tx On.Tx On.Tx Tx.naïve Off.Tx.CR Tx.naïve On.Tx <100 <100 <100 CLLV5 CLLV6 Female Female Female Female Male Male Male Female Male <100 <100 3461 <100 <100</p>
<10 CLLV7
CLLV8
CLLV9
CLLV10
CLLV11
CLLV12
CLLV13
CLLV14
CLLV15
CLLV16
CLLV17 <100 37157 870 18335 <100 <100 <100 <100 >312500 16255 262114 <100 533 <100 <100 <100 10300 247 5265 <100 <100 <100 <100 Tx.naïve On.Tx On.Tx <100 Tx.naïve Female Male <100 Tx.naïve
On.Tx
On.Tx
On.Tx
Tx.naïve
Tx.naïve
Tx.naïve
Tx.naïve
ff.Tx.and.R/R
Tx.naïve
On.Tx
On.Tx
Tx.naïve 352 <100 <100 42825 184 13018 2022 3170 <100 6938 <100 <100 <100 <100 15085 <100 <100 608 <100 <100 <100 11303 ND ND ND <100 161466 110325 ND ND ND Female Female Female Male CLLV18
CLLV19
CLLV20
CLLV21
CLLV22
CLLV23
CLLV24
CLLV25
CLLV26
CLLV27
CLLV28 <100 <100 >312500 6770 164471 13899 37209 <100 Male Male Male Female Male <100 <100 Female Male 148175 23339 10869 166 2942 <100 2913 <100 731 254 790 342 647 >312500 Female
Male
Male
Male
Male
Female
Female
Male Tx.naïve Tx.naïve 6293 51890 <100 383 <100 1809 <100 123 253 169 171 198 14039  $\begin{array}{c} \text{ND} \\ \text{ND} \\$ CLLV28
CLLV30
CLLV31
CLLV32
CLLV33
CLLV34
CLLV35
CLLV36
CLLV37 Tx.naïve
On.Tx
Tx.naïve
Off.Tx.and.R/R
Tx.naïve
Tx.naïve <100 <100 43861 <100 15965 11569 15389 Female Female Tx.naïve Off.Tx.CR 9254 13147 36 37 Tx.naïve Female Male Off.Tx.CR 31919 >312500 2095 Off.Tx.CR
Tx.naïve
On.Tx
Off.Tx.and.R/R
On.Tx
On.Tx
On.Tx
Tx.naïve
On.Tx
Tx.naïve
Off.Tx.CR
Tx.naïve CLLV38 CLLV39 Male Male 5424 <100 89373 <100 20417 <100 <100 <100 <100 12788 <100 <100 60781 1134 4204 <100 <100 14991 16666 <100 19650 16644 Female
Female
Female
Female
Female
Female
Female
Female CLLV40
CLLV41
CLLV42
CLLV43
CLLV44
CLLV45
CLLV46
CLLV47
CLLV48
CLLV49
CLLV50 <100 <100 <100 1302 3175 <100 662 19885 <100 <100 <100 21707 46365 <100 12679 Female 303589 Tx.naïve Female Male Female Male Female Male Male Male Female 258 4612 Off.Tx.and.R/R On.Tx On.Tx 4335 <100 <100 3800 2740 <100 <100 2616 6062 4564 80421 <100 CLLV50 CLLV51 CLLV52 CLLV53 CLLV54 CLLV55 CLLV56 CLLV57 CLLV58 CLLV59 <100 Tx.naïve Off.Tx.CR ff.Tx.and.R/R Tx.naïve 66371 29793 <100 1672 Tx.naïve Tx.naïve 51938 141781 7036 3255 <100 <100 Tx.naïve Female Male 76566 Off.Tx.and.R/R 305 11023 <100 <100 13804 CLLV60 CLLV61 Tx.naïve On.Tx Male Male 100 <100 <100 3920 6708 <100 867 <100 2917 118 7678 4297 13105 ND ND ND ND ND ND ND 12730 ND 14683 On.Tx Tx.naïve Tx.naïve On.Tx Tx.naïve On.Tx Off.Tx.CR Tx.naïve Tx.naïve CLLV61 CLLV62 CLLV63 CLLV64 CLLV65 CLLV66 CLLV67 CLLV68 CLLV69 CLLV70 Male
Male
Male
Male
Male
Male
Male
Female
Male
Male
Male 179944 67311 89175 <100 16804 <100 40868 1516 107963 386 <100 18279 <100 767 <100 15249 16099 451 654 >312500 28720 <100 1795 <100 8617 1000 36581 1676 >312500 <100 17017 <100 105371 14080 >312500 On.Tx On.Tx Off.Tx.CR Female Male Male 22342 <100 <100 1999 <100 230 <100 744 454 281 212 16113 CLLV71 CLLV72 <100 4584 <100 115885 ND ND 4230 ND ND ND ND CLLV72
CLLV73
CLLV74
CLLV75
CLLV76
CLLV77
CLLV78
CLLV79
CLLV80 4584 <100 188 <100 2733 2128 On.Tx On.Tx On.Tx On.Tx Tx.naïve On.Tx Female
Male
Male
Female
Female
Male
Female
Male <100 8745 <100 <100 34931 26777 44698 62799 Tx.naïve 2903 3929 25803 43683 Female Female Male Off.Tx.and.R/R 62608 >312500 On.Tx <100 <100 <100 <20
41
<20
548
<20
<20
<20
<20
<20
101
30
<20
139
134 1509 <100 22404 CLLV82 CLLV83 Tx.naïve On.Tx Female Male 18125 1313 <100 76049 6252 <100 <100 1723 5827 15895 <100 <100 <100 CLLV83
CLLV84
CLLV85
CLLV86
CLLV87
CLLV88
CLLV89
CLLV90
CLLV91 >312500 5557 263 <100 <100 169 284 2163 <100 <100 Tx.naïve
Tx.naïve
Tx.naïve
Tx.naïve
Tx.naïve
Off.Tx.CR
Tx.naïve
Tx.naïve Female Female Male Female Male Male Male Female 1384 1791 <100 555 1861 10348 1371 <100 17623 10231 <100 11537 16261 92902 16682 On.Tx Female <100 CLLV93 CLLV94 Tx.naïve Tx.naïve Female Male 3695 5006 70113 1864 1176 18575 15881 94551

-BY 4.0 International license.

Assay sensitivity cut-off values for Spike and RBD were >100; for the D614G and Delta neutralization assays >20; and >90% for RBD/ACE2 binding

Table S3. Serologic responses and univariate analyses for SARS-CoV-2 vaccinated healthy controls and CLL patients by disease status, Related to Figure 1.

А.							
Q	uantitation of serologic re	sponses	for healthy cor	ntrol and CLL	patients b	y disease stat	tus
		HC	Total CLL	Tx naïve	On Tx	Off Tx CR	Off Tx and R/R
Spike	n	30	95	45	34	9	7
EP	Responders	30	65	43	9	9	4
	Response rate (%)	100	68.4	95.6	26.5	100	57.1
EC <sub>50</sub>	Median	15355	662	2733	<100	2740	305
	IQR	27245	3595	5137.5	0	12885	4235
	95% CI of median						
	Lower confidence limit	9754	188	1000	<100	870	100
	Upper confidence limit	23979	1791	3800	<100	19885	62608
RBD	n	30	95	45	34	9	7
EP	Responders	30	51	35	4	9	3
	Response rate (%)	100	53.7	77.8	11.8	100	42.9
EC <sub>50</sub>	Median	3530	118	263	<100	708	<100
- 00	IQR	8376	608	1690	0	2863	66
	95% CI of median						
	Lower confidence limit	2396	100	169	<100	247	<100
	Upper confidence limit	6343	212	1172	<100	3338	16113
D614G	n	30	95	45	34	9	7
Neut ID <sub>50</sub>	Responders	29	40	28	1	8	3
30	Response rate (%)	96.7	42.1	62.2	2.9	88.9	42.9
	Median	463.9	<20	30.0	<20	65.1	<20
	IQR	995.8	81.5	249	0	347.8	647.4
	95% CI of median						-
	Lower confidence limit	367.8	<20	<20	<20	21.8	<20
	Upper confidence limit	1046.0	21.8	139.5	<20	508.4	2255
Delta	n	30	93	45	32	9	7
Neut ID <sub>50</sub>	Responders	28	35	24	1	7	3
	Response rate (%)	93.3	37.6	53.3	3.1	77.8	42.9
	Median	345.9	<20	20.5	<20	156.4	<20
	IQR	713.1	105	262.8	0	396.1	287.7
	95% CI of median						
	Lower confidence limit	170.7	<20	<20	<20	<20	<20
ACE2/RBD	Upper confidence limit	651.2	<20	123.4	<20	497.8	2604
binding (%)	n Beenendere	30 30	95 28	45 19	34 0	9 7	7 2
billuling ( //s)	Responders Response rate (%)	100	28 29.5	42.2	0	77.8	28.6
	Median	16	29.5 >90	>90	>90	77.6 58.7	>90
	IQR	29.4	34.4	57.0	0	69.3	36.0
	95% Cl of median	20	·	00	·	00.0	55.5
	Lower confidence limit	5.5	>90	62.2	>90	15.4	7.3
	Upper confidence limit	22.3	>90	>90	>90	>90	>90
	Abbreviations: EP - endno	:-+ FO	16	Z L		la alforacións a	

Abbreviations: EP - endpoint; EC<sub>50</sub>, half-maximal effective concentration; ID<sub>50</sub>, half-maximal neutralizing titers; Tx, treatment; CR, clinical remission, R/R, relapsed refractory.

В.							
	Univaria	te analysis of respo	onse rates and medi	ian titers by serolo	gic category and CLL d	isease status	
		Naïve vs. On Tx	Naïve vs. Off Tx CR	Naïve vs. Off Tx and R/R	On Tx vs. Off Tx CR	On Tx vs. Off Tx and R/R	Off Tx CR vs. Off Tx and R/R
Spike	Fisher's P value	<0.0001	>0.9999	0.0139	<0.0001	0.1807	0.0625
EC <sub>50</sub>	Odds ratio 95% CI Dunn's P value	59.72 12.08 to 269.4 <0.0001	0.000 0.000 to 11.08 >0.9999	16.13 2.422 to 100.5 >0.9999	0.000 0.000 to 0.1973 0.0001	0.27 0.06102 to 1.207 0.3552	+infinity 1.339 to +infinity 0.6165
RBD	Fisher's P value	<0.0001	0.1832	0.0745	<0.0001	0.082	0.0192
EC <sub>50</sub>	Odds ratio 95% CI Dunn's P value	26.25 7.086 to 77.69 <0.0001	0.000 0.000 to 1.834 0.6814	4.667 1.066 to 20.22 0.5688	0.000 0.000 to 0.09316 <0.0001	0.1778 0.02802 to 0.9590 >0.9999	+infinity 1.377 to +infinity 0.0759
D614G	Fisher's P value	<0.0001	0.244	0.4205	<0.0001	0.0121	0.1058
Neut ID <sub>50</sub>	Odds ratio 95% CI Dunn's P value	54.35 7.844 to 572.7 <0.0001	0.206 0.01763 to 1.327 >0.9999	2.196 0.5279 to 9.407 >0.9999	0.004 0.0003463 to 0.07701 0.0009	0.0404 0.003069 to 0.3710 0.1699	10.67 0.7953 to 143.0 >0.9999
Delta	Fisher's P value	<0.0001	0.2728	0.6983	<0.0001	0.014	0.3024
Neut ID <sub>50</sub>	Odds ratio 95% CI Dunn's P value	35.43 5.150 to 376.3 0.0006	0.327 0.06427 to 1.493 0.4768	1.524 0.3707 to 6.544 >0.9999	0.009 0.0008165 to 0.1287 0.0003	0.04301 0.003261 to 0.3953 0.2077	4.667 0.5081 to 31.88 >0.9999
ACE2/RBD	Fisher's P value	<0.0001	0.0721	0.6872	<0.0001	0.0256	0.1262
binding (%)	Odds ratio 95% CI Dunn's P value	+infinity 5.855 to +infinity <0.0001	0.2088 0.04142 to 0.9710 0.2507	1.827 0.3181 to 9.849 >0.9999	0.000 0.000 to 0.05514 <0.0001	0.000 0.000 to 0.4059 >0.9999	8.75 0.9391 to 61.89 0.0954

Dichotomous variables were calculated by Fisher's exact test. P values for differences in medians were calculated by Dunn's multiple comparisons test

Table S4. Clinical determinants of serologic and neutralizing responses in CLL vaccinees, Related to Figures 1 & 4.

### A. Categorical univariate analysis

Clinical Variable	Spike (EP)	RBD (EP)	D614G (Neut ID <sub>50</sub> )	Delta (Neut ID <sub>50</sub> )	ACE2/RBD Binding
Age ≥ 65 yo	NS	NS	NS	NS	NS
Gender	NS	NS	NS	NS	NS
Disease status	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
Rai stage II-IV (no)	NS	0.038	0.034	NS	NS
IGHV mutation status (MT)	0.031	0.013	NS	NS	NS
CD38 >20%	NS	NS	NS	NS	NS
FISH cytogenetics	NS	NS	NS	NS	NS
β2-microglobulin ≤ 2.4	0.0015	0.023	< 0.0001	0.0094	0.013
Prior therapy (no)	< 0.0001	< 0.0001	< 0.0001	0.0030	0.013
Anti CD20 ≥ 12 months	0.0082	0.0011	0.0030	0.0075	0.018
BTK inhibitor therapy	NS	NS	NS	NS	NS
ALC < 5,000, (10 <sup>9</sup> /L)	0.047	0.014	NS	NS	NS
IVIg prophylaxis (no)	0.0011	0.019	0.010	0.052	NS
IgG ≥ 650 mg/dL	0.010	0.0027	NS	NS	NS
IgM ≥ 40 mg/dL	NS	NS	NS	NS	NS
IgA ≥ 60 mg/dL	NS	0.035	NS	NS	NS
Pfizer or Moderna vaccine	NS	NS	NS	NS	NS
Months from vaccination	NS	0.046	NS	NS	NS

Comparisons between variables were calculated by Fisher's exact test.

Assay sensitivity cut-off values for Spike and RBD were >100; for the D614G and Delta neutralization assays >20; and >90% for RBD/ACE2 binding.

Correlates with significant p values are highlighted green.

Note disease status and months from vaccination encompass multiple catagories.

Abbreviations: EP, endpoint titer; Neut ID50, half-maximal neutralizing titer; NS, not significant; IGHV, immunoglobulin heavy chain variable region gene; MT, mutated; FISH, fluorescence in situ hybridization; BTK, Bruton's tyrosine kinase; ALC, absolute lymphocyte count; IVIg, intravenous immunoglobulin; Pfizer-BioNTech, BNT162b2; Moderna, mRNA-2173.

### B. Multivariate analysis

Clinical Variable		Spike (I	EP)	D614G (Neut ID <sub>50</sub> )							
	P value	OR	95% CI	P value	OR	95% CI					
Age ≥ 65 yo	0.26	0.42	0.079-1.9	0.87	1.1	0.29-4.5					
Male sex	0.65	1.4	0.36-5.6	0.69	1.3	0.37-4.4					
Rai stage II-IV	0.63	1.8	0.14-18	0.24	3.5	0.46-56					
Unmutated IGHV	0.94	0.93	0.11-6	0.83	1.2	0.28-5.1					
On therapy	0.0028	62	3.6-3500	0.041	40	1.2-2500					
Off therapy and R/R	0.038	7.7	1.1-64	0.6	1.7	0.25-13					
Off therapy CR	0.54	3.7	0.018-250	0.81	0.71	0.034-17					
ALC > 5,000, (10 <sup>9</sup> /L)	0.3	3.8	0.37-130	0.13	5.2	0.65-110					
IVIg prophylaxis therapy	0.018	5.2	1.3-29	0.052	4.4	0.99-25					
Pfizer vaccination	0.59	1.4	0.39-5.9	0.0056	5.8	1.6-27					
2 months from vaccination	0.3	2.3	0.49-12	0.9	1.1	0.24-5					
>3 months from vaccination	0.51	0.59	0.11-2.8	0.91	1.1	0.25-5					

Firth logistic regression was used to examine the association of serological responses with clinical variables.

Abbreviations: R/R, relapsed refractory; CR, clinical remission.

Table S5. Subset frequencies, SARS-CoV-2 S peptide-specific AIM responses, and effector functions in healthy control and CLL donor T cells, Related to Figures 2, 5, S1 & S2.

Α.					CD4 T cell frequencies CD8 T cell frequencies										N-specific T cell subset		C.			enecific T	call subset	t AIM roo	Inonese		1 <sup>D.</sup>				S.enacifi	r T cell c	uheat affact	fector functions of healthy control and CLL vaccinees											
			Total T cells	Total			emory subse	to	Total			mory subsets		AIM responses AIM responders				S-specific T cell subset AIM responses  AIM responders Response frequencies					4										98 T cells										
ID	Status	Gender	cells	Iotal		(naive)Q2:	(Terma)Q3:	(Tem)Q4:	I otal	(Tcm)Q1:	(naive)Q2:	(Terma)Q3:	(Tem)Q4:		AIN	I respond	ders			All	responde	rs	1	Kesponse	e trequencies		IC	S I cell re	sponders	_		CD4	I cells				CL	8 I cells		-			
			CD19- CD3+	CD3+ CD4+	CD45RA-, CCR7+	CD45RA+, CCR7+	CD45RA+, CCR7-	CD45RA- CCR7-	CD3+ CD8+	CD45RA-, CCR7+	CD45RA+, CCR7+	CD45RA+, CCR7-	CD45RA-, CCR7-	ID		Tfh CD8		ID	CD4	cTfh	CD8	Positive (S)	SUM (S)		cTfh CD8	ID	CD4	CD8		SUM (S) IF		IFα IL2	Grz-B	Perforin			NFα IL2		Perforin	PFS			
1 HC2 2 HC5	Healthy Healthy	Female Male	80.7 74.1	80.2 79.1	30.9 24.9	49.8 36.5	2.4 6.16	16.9 32.5	17.1 10.3	10 8	27.1 30.1	38 21.5	24.8 40.4	HC2 HC5		0 0		HC2 HC5	1	0	0	1	1		2.13 0.28 0.00 0.09	HC2 HC5	1	0	1			064 0.070 065 0.069		0.002			.016 0.07			0.197			
3 HC8	Healthy	Male	77.9	77.2	25.7	37.2	6.69	30.4	16.3	2.95	1.85	74.1	21.1	HC8	0	0 0	0	HC8	1	1	1	1	3	0.83	2.81 0.20	HC8	1	1	1	2 0.0	0.0	0.119	0.001	0.003	0.241	0.000 0	.000 0.16	0.000		0.121			
4 HC9 5 HC11	Healthy Healthy	Female Male	82.1 85.6	91.3 87.7	36.6 23.1	46.6 60.9	2.96 2.33	13.8 13.6	4.92 7.69	8.47 9.01	17.8 23.4	48.5 21.5	25.2 46	HC9 HC11	0	0 0	0	HC9 HC11	1	0	0	1	1 2		0.61 0.00 2.74 0.00	HC9 HC11	1	0	1		0.0	0.021 031 0.032					.000 0.00						
6 HC13	Healthy	Male	40.9	92.9	30.4	36.5	4.04	29.1	3.32	3.22	14.8	56.6	25.4	HC13	ő	0 0	ő	HC13	ó	o o	ő	ó	ō	0.00	0.59 0.00	HC13								0.000				0.000	0.000				
7 HC14 8 HC15	Healthy Healthy	Female Female	80.3 86.9	80.2 92.9	17.7 27.1	44.4 53.1	4.56 2.6	33.4 17.2	13.8	5.09 18.5	20.2 47.7	32.9 6.68	41.8 27.1	HC14 HC15		0 0		HC14 HC15	1	1	0	1	2		2.13 0.15 4.35 0.07	HC14ª HC15	ND 1	ND 1	ND 1	ND N 2 0.0		D ND 050 0.101	ND 0.000	ND 0.000	ND 0.272		ND NE .036 0.12	ND 23 0.005	ND 0.013	ND 0.234			
9 HC16	Healthy	Female	90.1	81.5	28.2	33.9	5.04	32.9	13.4	18.5	39.3	12.2	30	HC16		0 0		HC16	1	1	1	1	3	1.44	1.31 0.44	HC16	1	1	1			0.129	0.000	0.000	0.250	0.156 0	.097 0.12		0.013	0.293			
10 HC17 11 HC18	Healthy Healthy	Female Male	90 80.2	76.2 86	26.7 22.3	36.8 23.2	6.08 10.7	30.4 43.8	18.3 7.17	7.33 9.86	22.1 26.1	38.3 18.9	32.2 45.1	HC17 HC18		0 0		HC17 HC18	1	1	1	1	3		0.57 0.20 0.18 0.90	HC17 HC18	1	1	1			162 0.090 210 0.190					.085 0.00			0.264			
12 HC20	Healthy	Male	76.7	82.1	27.7	38.8	5.5	43.6 28	8.4	6.26	45.2	21.7	26.9	HC20		0 0		HC20	1	1	o	1	2		0.18 0.90	HC20	1	1	1			0.190		0.000	0.342	0.295 0	.000 0.38		0.020				
13 HC21	Healthy	Male Male	76.5	77.4	26.8	41.6	8.2	23.4	7.27	13.8	31.9	9.45	44.9	HC21		0 0		HC21	1	1	1	1	3		0.34 0.51	HC21	1	1	1			0.136					.019 0.00						
14 HC22 15 HC23	Healthy Healthy	Female	80.3 89.4	65.1 72.3	23.5 25.4	46.5 39.8	6.67 7.94	23.3 26.8	19.7 21.2	32.6 9.66	28.7 27.2	14.6 17.9	24.1 45.3	HC22 HC23		0 0		HC22 HC23	1	1	1	1	3		0.43 0.17 3.01 0.19	HC22 HC23	1	1	1	2 0.0	0.0	0.054	0.000	0.002	0.329	0.148 0	.030 0.06	0.000	0.000	0.187			
16 HC24	Healthy	Male	78.7	66.8	30.4	50.6	2.36	16.6	22.8	7.69	53	4.56	34.7	HC24		0 0		HC24	1	1	0	1	2		0.54 0.11	HC24	1	1	1			0.079					.016 0.11			0.242			
17 HC25 18 HC26	Healthy Healthy	Male Male	80.4 60.9	53.1 82.5	22.3 19.7	24.7 42.4	5.42 9.66	47.5 28.2	16.7 4.49	7.19 6.69	12.8 45.9	9.25 5.42	70.8 42	HC25 HC26"	-	0 0 ND ND		HC25 HC26	1	1	0	1	2		0.98 0.09 1.38 0.00	HC25 HC26 <sup>a</sup>	ND	ND ND	ND ND	ND N		0.037 D ND	0.000 ND	0.000 ND	0.190 ND		.007 0.00 ND NE		0.000 ND	0.233 ND			
19 HC28	Healthy	Male	79.1	72.9	23.2	42.9	3.94	30	18.3	10.4	3.77	51.6	34.3	HC28		0 0		HC28	ó	1	ő	i	1		1.64 0.30	HC28	1	1	1			0.138			0.172		.030 0.17			0.177			
20 HC30	Healthy	Male	76	86.3	29.6	46.4	3.8	20.2	5.62	17.7	19.7	3.63	59	HC30"		ND ND		HC30	0	1	1	1	2		0.78 0.14	HC30*	ND	ND	ND	ND N	D N	D ND	ND	ND	ND	ND	ND NE	ND ND	ND	ND			
21 HC31	Healthy	Male	84.6	40.6	17.2	26.7	11.2	44.9	8.65	9.95	18.4	32.6	39	HC31ª	ND N	ND ND		HC31	0	0	0	0	0		0.41 0.01	HC31		-															
1 CLLV1 2 CLLV2	On.Tx Tx.naïve	Male Male	81.1 7.79	81.4 82.1	10.4 45.4	50.5 26.2	15.4 1.5	23.7 27	11.8	1.99 13.9	8.55 21	72.5 35.9	29.1	CLLV1 CLLV2	0	0 0		CLLV1 CLLV2	0	0	0	0	0		2.040 0.401 0.000 0.000	CLLV1 CLLV2	1	1	1	2 0.0	0.0	0.462	0.000	0.000	0.216	0.124 0	.237 0.09	0.006	0.009	0.303			
3 CLLV6	On.Tx	Female	46.6	75.3	37.5	16	15.9	30.6	9.12	11.1	10.7	37.5	40.7	CLLV6		0 0		CLLV6	0	0	0	0	0		0.000	CLLV6	_		_			040 0.041					.002 0.03		0.013				
4 CLLV12 5 CLLV21	Tx.naïve Tx.naïve	Male Male	13.2 33.6	67.7 68.5	37.7 19.1	18.3 25.5	4.32 15.1	39.7 40.4	28.1 16.3	2.88 2.52	1.57 2.72	39.2 59.4	56.4 35.3	CLLV12 CLLV21		0 0		CLLV12 CLLV21	0	0	0	0	0		0.038 0.023	CLLV12 CLLV21	0	0	0	0 0.0	0.0	0.041	0.000	0.000	0.132	0.015 0	.002 0.03	94 0.028	0.013	0.071			
6 CLLV23	Tx.naïve	Female	9.91	85.6	40.4	32.9	2.48	24.3	9.12	16.1	11.4	26.9	45.6	CLLV23		0 0	0	CLLV23	0	0	0	0	0		0.000 0.160	CLLV23																	
7 CLLV27 8 CLLV30	Tx.naïve Tx.naïve	Female Male	15.1 2.12	68.1 88	16.2 19.6	50.9 44.3	7.62 7.08	25.3 29	23.2 8.37	2.03 1.26	11.7 10.6	66.5 32.6	19.7 55.6	CLLV27 CLLV30		0 0		CLLV27 CLLV30	0	0	0	0	0		0.000 0.008	CLLV27 CLLV30																	
9 CLLV31	Off.Tx.and.R.R	R Female	7.78	45.2	19.7	3.3	4.09	72.9	44.6	2.9	1.45	52.2	43.4	CLLV31		0 0	0	CLLV31	ō	ō	ō	ō	ō	0.000	0.000	CLLV31																	
10 CLLV33 11 CLLV34	Tx.naïve Tx.naïve	Male Female	37.9 19.5	42.4 76.1	38.7 30.7	31.7 5.89	6.67 8.08	23 55.3	37.8 11.1	1.91 13.5	0.6 1.81	71 26.7	26.5 57.9	CLLV33 CLLV34		0 0		CLLV33 CLLV34	0	0	0	0	0		0.000 0.051	CLLV33 CLLV34																	
12 CLLV35	Off.Tx.CR	Female	42.7	72	19.3	48.5	5.05	27.2	20.3	5.16	45	12.3	37.5	CLLV35	0	0 0	0	CLLV35	0	0	0	0	0	0.031	0.000 0.059	CLLV35																	
13 CLLV36 14 CLLV40	Tx.naive Off.Tx.and.R.R	Female R Female	3.3	63.5 51.8	51.6 20.8	21.5 14.5	4.05 11	22.8 53.7	18.3 39.8	27.3 6.29	10.7	5.81 22	56.2 70.7	CLLV36 CLLV40		0 0		CLLV36 CLLV40	0	0	0	0	0		0.000 0.500	CLLV36 CLLV40														4			
15 CLLV47	Off.Tx.CR	Female	55.3	74.3	21.3	9.52	9.27	59.9	21.2	18	6.8	16	59.2	CLLV47	0	0 0	0	CLLV47	o	ō	ō	0	0	0.000	0.140 0.038	CLLV47																	
16 CLLV48 17 CLLV49	Tx.naive Off.Tx.and.R.R	Female R Male	16 2.45	75.5 64.5	14.9 41.9	54.2 3.33	7.98 3.88	23 50.9	21.5 25.6	2.04	2.33 1.08	10 25.4	85.6 54.6	CLLV48 CLLV49		0 0		CLLV48 CLLV49	0	0	0	0	0		0.680 0.000 1.230 0.180	CLLV48 CLLV49																	
18 CLLV50	On.Tx	Female	6.36	54.5	17.2	15.5	6.11	61.2	37.8	3.8	3.46	28.8	63.9	CLLV50	0	0 0	0	CLLV50	o o	0	ő	o o	o	0.000	0.000	CLLV50																	
19 CLLV51 20 CLLV54	On.Tx Off.Tx.and.R.R	Male R Female	80.1 4.04	88.1 76.1	12.9 19.1	33.1 70.1	17.9 2.51	36.2 8.33	5.85 6.2	5.04 8.61	25.3 26	27.1 26.5	42.5 39	CLLV51 CLLV54		0 0		CLLV51 CLLV54	0	0	0	0	0		0.920 0.000	CLLV51 CLLV54																	
21 CLLV55	Tx.naive	Male	3.78	34.3	30.8	14.5	8.49	46.2	42	11.7	7.08	8.23	72.9	CLLV55		0 0		CLLV55	1	1	0	1	2		2.600 0.079	CLLV55	0	1	1	1 0.1	130 1.3	0.400	0.000	0.031	0.176	0.570 0	.440 0.00	0.000	0.046	0.198			
22 CLLV57 23 CLLV58	Tx.naïve Tx.naïve	Female Female	1.64	54 75	40.1 22.7	41.9 46.9	2.31 10.5	15.6 19.8	32.6 15.1	19.5 8.42	8.22 53.2	18.6 30.6	53.7 7.81	CLLV57 CLLV58		0 0		CLLV57 CLLV58	0	0	0	0	0		0.240 0.000 2.170 0.352	CLLV57 CLLV58		0	0	0 00	000 0.1	110 0.064	0.000	0.000	0.052	0.000	.000 0.00	0.000	0.000	0.000			
24 CLLV59	Off.Tx.and.R.R	R Male	2.34	88.1	29.7	39.3	3.78	27.1	7.87	11.8	24.4	12.2	51.6	CLLV59		0 0		CLLV50	1	0	0	1	1		0.930 0.053	CLLV59	U	U	U	0 0.0	0.1	0.064	0.000	0.000	0.052	0.000	.000	0.000	0.000	0.000			
25 CLLV60 26 CLLV61	Tx.naïve On.Tx	Male Male	20.9 49	51.4 94.5	29 20.6	16.1 27.7	6.57 13.5	48.4 38.2	29.1 1.47	5.1 14.6	3.18 8.21	27 14.9	64.7 62.3	CLLV60 CLLV61		0 0		CLLV60 CLLV61	0	0	0	0	0		0.000 0.050 0.110 0.000	CLLV60 CLLV61																	
26 CLLV61 27 CLLV62	Tx.naive	Male	12.4	94.5 79.6	21	33.3	9.63	36	12.5	11.6	5.41	36.6	62.3 46.3	CLLV62		0 0		CLLV62	0	0	0	0	0	0.430	0.000 0.042	CLLV61																	
28 CLLV64	On.Tx	Male	72.2	47	26.8	33	4.8	35.4	32.1	5.4	6.73	12.8	75	CLLV64		0 0		CLLV64	1	0	0	1	1		0.000 0.033	CLLV64	0	0	0	0.0	0.0	0.000	0.050	0.150	0.000	0.000 0	.470 0.00	0.040	0.030	0.001			
29 CLLV65 30 CLLV69	Tx.naïve Tx.naïve	Male Male	9.94	88.2 77.6	21.6 25.2	57.3 53.9	2.85 3.53	18.3 17.4	9.1	4.85 12.4	7.67 14.5	49.5 19.8	37.9 53.3	CLLV65 CLLV69		0 0		CLLV65 CLLV69	0	0	0	0	2		0.060 0.000	CLLV65 CLLV69*	ND	ND	ND	ND N	D N	D ND	ND	ND	ND	ND	ND NE	ND ND	ND	ND			
31 CLLV70	On.Tx	Female	1.48	71	10.8	80.3	2.4	6.45	24.7	1.92	23.2	41.7	33.2	CLLV70		0 0		CLLV70	0	o	0	0	0		2.820 0.000	CLLV70	.40					- ND	ND				, INC	, IND	.40				
32 CLLV75	On.Tx	Male	5.32	49.9	14.6	13.6	10	61.7	42.1	6.54	1.68	14	77.8	CLLV75		0 0		CLLV75	0	0	- 1	- 1	1		0.130 0.085	CLLV75 <sup>a</sup>		ND	ND	ND N		D ND	ND	ND	ND		ND NE		ND	ND			
33 CLLV78 34 CLLV80	Tx.naive Off.Tx.and.R.R	Male R Female	11.3 4.44	59.2 56.4	24.4 33.4	27.2 15.9	5.13 3.59	43.3 47.1	14.8 39.9	2.36 5.84	7.13 1.07	38.1 20.6	52.4 72.4	CLLV78 CLLV80		0 0		CLLV78 CLLV80	1	1	0	1	2		1.960 0.106 0.000 0.009	CLLV78 <sup>a</sup> CLLV80	ND	ND	ND	ND N	D N	D ND	ND	ND	ND	ND	ND NE	) ND	ND	ND			
35 CLLV84	Tx.naïve	Female	14.4	61.9	36.8	16.9	5.55	40.8	31.7	8.26 15.1	3.79	26.9 36.2	61.1	CLLV84		0 0		CLLV84	1	1	0	1	2	0.139	0.000	CLLV84	0	1	1			0.000		0.000			.004 0.00			0.182			
36 CLLV86	Tx.naïve	Female	34.7	66	32.2	41.8	2.05	34.6	CLLV86	0	0 0	0	CLLV86	0	0	1	1	1	0.170	0.820 0.173	CLLV86	1	1	1	2 0.0	0.1	0.050	0.000	0.000	0.167	0.046 0	.020 0.04	0.021	0.008	0.204								
Values shown for T cell subpopulations indicate frequencies (%) as determined by flow cytometry analysis.												*Material wa assay on th			n tne	Values of "	I" indicate the	e presence a	and "0" the a	absence of a	respons	e.		*Material w	as not avai	able to run	the assay o	n these sar	mples.														
	assay on the													noo ond	Values abo	en for T coll o	ou boon dotic	n roononoo	n indicate for	oguenolos	o (95) on dator	rmined by flow																					

Abbreviations: Tx, treatment; CR, clinical remission, R/R, relapsed refractory.

Values of "1" indicate the presence and "0" the absence of a response.

Values of "1" indicate the presence and "0" the absence of a response.

Values of "1" indicate the presence and "0" the absence of a response.

Values of "1" indicate the presence and "0" the absence of a response.

Values of "1" indicate the presence and "0" the absence of a response.

For values left blank data are not applicable.

Values of "1" indicate the presence and "0" the absence of a response.

For values left blank data are not applicable.

Values of "1" indicate the presence and "0" the absence of a response.

Values of "1" indicate the presence and "0" the absence of a response.

For values left blank data are not applicable.

Values of "1" indicate the presence and "0" the absence of a response.

Values of "1" indicate the presence and "0" the absence of a response.

For values left blank data are not applicable.

Values of "1" indicate the presence and "0" the absence of a response.

For values left blank data are not applicable.

Values of "1" indicate the presence and "0" the absence of a response.

For values left blank data are not applicable. Values shown for T cell subpopulation responses indicate frequencies (%) as determined by flow cytometry analysis. Abbreviations: ICS, intracellular cytokine staining; PFS, polyfunctionality score calculated by COMPASS; ND, no data.